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Abstract 
 Diabetes mellitus has become a global pandemic, with almost 350 million individuals 
world-wide affected by the disease. There are two common forms, characterized by either a lack 
of insulin production or peripheral insulin resistance. Diabetic peripheral neuropathy is the most 
common and debilitating complication in both forms, and approximately 30% of individuals with 
diabetic neuropathy will experience pain that significantly impacts their quality of life. 
Unfortunately, symptomatic treatment modalities are often ineffective and carry significant risk 
of systemic adverse effects.  
 The work contained herein used a rodent model of painful diabetic neuropathy following 
induction of diabetes with the pancreatic beta cell toxin, streptozocin (STZ). Results show that 
diabetes reduces the ability of specialized enzymes, termed ectonucleotidases, to hydrolyze 
extracellular AMP into the analgesic small molecule adenosine. At this same time, diabetic mice 
displayed significant mechanical allodynia, suggesting that altered adenosine production and 
decreased activation of the antinociceptive A1 adenosine receptor (A1R) may contribute to the 
development of painful diabetic neuropathy. 
 In the dorsal horn of the spinal cord, A1R is highly expressed where peripheral pain 
sensing neurons terminate, placing it in prime location to modulate nociceptive signaling. Central 
delivery of A1R agonists, such as AMP, adenosine and the specific A1R agonist, N6-
cyclopentyladenosine (CPA), significantly improved mechanical withdrawal thresholds in 
diabetic mice to levels that were not significantly different from nondiabetic mice. A1R is a G-
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protein coupled receptor whose activation results in initiation of downstream second messenger 
systems. Inhibition of cAMP production and robust activation of Akt were observed following 
central delivery of adenosine and CPA, suggesting these pathways contribute to the antiallodynic 
effects of activation of A1R.  
 Central delivery of A1R agonists is not ideal for translation to the human population. 
Accordingly, peripheral delivery methods were evaluated to determine the efficacy of this 
therapeutic intervention in painful diabetic neuropathy. Surprisingly, peripheral delivery of CPA 
resulted in significant improvement in mechanical allodynia in diabetic mice, confirming that the 
A1R-mediated antinociceptive pathway is accessible from the periphery. These observations 
warrant further investigation into this endogenous antinociceptive pathway for the development 
of novel therapeutic treatment options for individuals suffering from painful diabetic neuropathy.  
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CHAPTER 1 
 
Introduction 
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Diabetes Mellitus  
Diabetes mellitus has become a global pandemic, with over 347 million people affected 
world-wide [1]. In the United States more than 25 million people have diabetes (both diagnosed 
and undiagnosed), and almost 2 million new diagnoses were made in 2010 alone [2]. There is an 
alarming increase in the rate of pre-diabetes in the adult population with an estimated 35% of the 
population, or 79 million individuals, having abnormally elevated fasting blood glucose levels 
and/or hemoglobin A1c levels [2], placing them at increased risk for developing diabetes. Direct 
and indirect medical costs related to the care and treatment of diabetes exceed $174 billion 
annually [2].  
 Diabetes is a complex metabolic disorder that results from impaired insulin secretion or 
altered insulin sensitivity in peripheral tissues [2-5]. This results in fasting hyperglycemia, and 
elevated blood glucose levels can affect all tissues of the body. There are two main forms of 
diabetes mellitus, type 1 diabetes (T1D) and type 2 diabetes (T2D). Both types can result in the 
same long term sequelae, but they have different underlying pathologies. Type 1 diabetes 
accounts for 5-10% of all diagnosed cases of diabetes, and is mainly diagnosed in children and 
young adults [2, 6]. Most individuals world-wide are diagnosed with type 2 diabetes (T2D), 
which accounts for 90-95% of all diagnosed cases of diabetes [2, 3]. This form of diabetes is 
primarily diagnosed in adults and is associated with a sedentary lifestyle, obesity, and an 
unhealthy diet [2, 3]. The prevalence of juvenile T2D in the United States has increased in recent 
years due to increasing rates of childhood obesity [2, 3, 7]. 
Type 1 diabetes results from autoimmune destruction of beta cells in the pancreas, the 
primary insulin-producing cells of the body [6, 8]. Patients with T1D are unable to properly 
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synthesize insulin and, therefore, are unable to take up glucose resulting in a chronic state of 
hyperglycemia that leads to muscle and protein catabolism, often resulting in weight loss, 
polydipsia and polyuria [6]. The primary pathology of T2D is hyperglycemia due to decreased 
insulin sensitivity in insulin-responsive tissues. Ultimately, this increased insulin resistance 
results in impaired beta-cell production of insulin at which time patients with T2D become 
dependent on insulin replacement therapy [2, 3, 5]. Despite the underlying cause, all patients 
with diabetes are at increased risk for several long-term complications such as vascular disease, 
including myocardial infarction, stroke and hypertension; kidney disease (diabetic nephropathy); 
blindness (diabetic retinopathy); and nerve damage (diabetic neuropathy) [2, 3].  
 
Diabetic Neuropathy 
Clinical manifestations 
Diabetic peripheral neuropathy is the most common and debilitating complication 
experienced by persons with diabetes [5, 9-11], and it can affect sensory, motor and autonomic 
peripheral neurons. Shockingly, up to 70% of patients with diabetes suffer complications related 
to the nervous system [2], affecting patients with both T1D and T2D. The most common 
manifestation is a length-dependent polyneuropathy (also known as distal symmetric 
polyneuropathy) that preferentially targets the longest axons of the body first, although other 
types of neuropathy are also prevalent in diabetes [12]. Due to the length-dependent destruction 
of nerves, symptoms are often first noticed in the feet where the longest axons of the body 
terminate, and symptoms can be either focal or diffuse in nature. Symptoms begin in the 
extremities and then progress proximally in a length-dependent fashion, often referred to as a 
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stocking-and-glove pattern of sensory loss, with sensory loss predominant over motor symptoms 
[4, 9]. Patients with diabetic neuropathy experience a variety of symptoms ranging from 
increased sensations such as tingling, burning, or pins-and-needles sensations (referred to as 
paresthesias), heightened sensitivity to normally innocuous stimuli (allodynia) or exaggerated 
responses to normally painful stimuli (hyperalgesia). On the other hand, patients can experience 
loss of sensation that includes numbness, weakness, and loss of proprioception, placing them at 
increased risk for falls [5, 9].  
Altered sensation as a consequence of diabetic peripheral neuropathy can result in the 
development of several other physical pathologies. Loss of sensation in the feet can lead to the 
development of foot ulcers, as patients with diabetic neuropathy are unable to feel the initiation 
and development of lesions on the feet. If not cared for properly this loss of sensation, in 
combination with impaired wound healing, can result in the development of severe infections 
and ulcers, and in extreme cases can lead to amputation. Indeed, diabetic neuropathy is one of 
the leading causes of non-traumatic lower-limb amputation in the United States [2, 9, 13]. 
Furthermore, loss of proper nerve function can lead to impaired proprioception, placing patients 
with diabetes at increased risk for falls [11]. Additionally, sensory loss can lead to the 
development of Charcot joint, a condition that is due to repetitive trauma and can result in 
fracture, dislocation, or deformation of the foot [14], which can further contribute to instability 
and falls. Carpal tunnel syndrome and ulnar nerve entrapment can significantly affect hand 
function and are more common in patients with peripheral neuropathy [5]. Other conditions 
secondary to diabetes-induced neuropathy include autonomic neuropathy (primarily affecting the 
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gastrointestinal tract), radiculoplexopathy (most commonly seen in the lumbosacral region), and 
other focal neuropathies [5, 9]. 
Diagnosis 
The American Diabetes Association and the American Academy of Neurology both 
recommend nerve conduction testing as an objective method of detecting peripheral neuropathy 
in patients with diabetes [12, 15, 16]. This test evaluates nerve conduction velocities in large 
myelinated fibers by measuring the time it takes for an electrical impulse to travel from the 
stimulus location to the recording location. Slowing of conduction velocities is indicative of 
neuropathy. However, diabetic neuropathy affects all fiber types, including large myelinated Aβ-
fibers, thinly myelinated Aδ-fibers, and unmyelinated C-fibers (discussed in detail below), and 
nerve conduction studies are, therefore, limited in that they are able to detect abnormalities only 
in large fiber types, which are generally affected late in disease progression [17].  
To augment the ability to detect changes in the peripheral nervous system, qualitative 
sensory tests (QSTs) are commonly used in clinical practice as a supplement to nerve conduction 
studies.  Qualitative sensory tests involve application of a stimulus to the foot and its detection 
by the patient. Mechanical sensitivity, heat and cold thresholds, vibratory sensation, and the 
presence or absence of ankle and/or lower extremity reflexes are common exams performed by 
clinicians to diagnose peripheral neuropathy [18-20]. These QSTs are easy to perform and are 
non-invasive; however, they are inherently variable due to inconsistencies in application and 
delivery of the exam [15, 21]. Nevertheless, QSTs are a suitable annual testing method for 
detecting the presence of neuropathy, and multiple positive signs are correlated with high 
sensitivity and diagnostic accuracy [15, 16].  
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Patients with small-fiber neuropathy often have normal electrophysiological studies, yet 
display signs and symptoms of neuropathy [22, 23]. Intraepidermal nerve fiber (IENF) densities 
have recently been used to identify small-fiber neuropathy and track the progression of diabetic 
neuropathy. This analysis involves direct visualization of nerve fibers in the skin [22, 24]. A 
small, 3-mm punch biopsy is taken, typically from the distal portion of the lower leg, and is then 
processed and stained with antibodies that detect all nerve fibers in the dermis and epidermis. 
These fibers are then counted to determine the average number of IENFs present in the region 
from which the skin was taken. If these values are lower than average, or if they decrease after 
repeated testing, then the patient is diagnosed as having small-fiber neuropathy. This test has 
relatively high diagnostic accuracy and is more sensitive than QSTs at diagnosing small-fiber 
neuropathy [22, 24]. It has been suggested that small-fiber neuropathy is one of the earliest signs 
of impaired glucose tolerance as a high percentage of patients with impaired glucose tolerance 
exhibit decreased IENF densities [20, 25]. A relatively new approach to identify patients at risk 
for diabetic neuropathy is corneal confocal microscopy [26]. The cornea is a highly innervated 
tissue, and contains a very high density of unmyelinated nerve fibers. This noninvasive technique 
is still in the developmental stages but has shown promise in that it can detect changes in corneal 
nerve fiber density, length, and branching, and these changes correlate with the severity of 
neuropathy.  
Pathogenesis of Diabetic Neuropathy 
Collectively, patients with diabetic neuropathy exhibit a variety of signs and symptoms, 
owing to damage of the different nerve fibers resulting from chronic hyperglycemia. Indeed, the 
severity of diabetic neuropathy correlates to the severity and duration of hyperglycemia [20]. 
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Tight glycemic control is currently the only proven disease modifying intervention for delaying 
progression of diabetic neuropathy [5, 9, 10, 16, 27, 28]. As was eluded to earlier, symmetrical 
loss of distal axons is a hallmark of diabetic peripheral neuropathy, with both small and large 
fibers affected [5]. Several histological abnormalities are present, affecting not only the nerves, 
but also the supporting cells and vasculature supplying the nervous system. Segmental 
demyelination and remyelination of nerve axons is present, and this can contribute to altered 
nerve conduction along the axon [4]. Alterations in the vasa nervorum can lead to neuronal 
ischemia and decreased diffusion of nutrients from the blood supply to the axons due to 
endothelial basement membrane thickening [4, 5]. Additionally, ‘onion bulb’ formation is often 
seen upon morphological examination of peripheral nerves, indicative of chronic and repeated 
demyelination and remyelination of the nerve [29]. 
A number of mechanisms underlying the pathogenesis of diabetic neuropathy have been 
explored, and it is likely a combination of vascular, immunological and metabolic abnormalities 
that ultimately leads to the development and maintenance of diabetic neuropathy. Excess glucose 
due to chronic hyperglycemia results in the movement of glucose through several different 
pathways [10, 20, 30, 31]. Glucose that cannot be broken down through glycolysis can enter the 
polyol pathway, resulting in increased oxidative stress. Elevated levels of fructose-6-phosphate 
and glyceraldehyde-3-phosphate, two intermediates of glycolysis, are transported through the 
hexosamine pathway and protein kinase C pathway, respectively, both resulting in altered gene 
expression. Glyceraldehyde-3-phosphate, as well as excess fructose from the polyol pathway, 
can contribute to the formation of advanced glycation end products (AGEs) leading to 
irreversible protein modifications. Additionally, free radical generation, decreased neurotrophic 
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support, altered mitochondrial function, and microvascular complications are all thought to 
contribute to the development of peripheral neuropathy. 
 
Painful Diabetic Neuropathy and Treatment  
A significant proportion of patients with diabetes experience pain, with estimates ranging 
from 10-20% of patients in the general diabetic population, and 40-60% of patients with 
documented diabetes-induced peripheral neuropathy [9, 17, 32]. This pain can be so severe that it 
significantly impacts patients’ quality of life, affecting their ability to walk, work, sleep, and 
their overall mood. Furthermore, patients with painful diabetic neuropathy report lower rates of 
self-management and exercise, and this is correlated with the severity of pain [32]. Additionally, 
healthcare costs for patients with painful diabetic neuropathy are up to three times higher than 
matched controls [17]. Individuals suffering from painful diabetic neuropathy often present with 
lancinating or shooting pain in the feet (paresthesias), allodynia and/or hyperalgesia, and 
symptoms often worsen at night. Symptoms associated with painful diabetic neuropathy are 
indicative of small-fiber (Aδ- and C-fiber) involvement.  
It is currently unknown why only a subset of patients with diabetic neuropathy develop 
chronic pain, when all patients presumably exhibit the same underlying mechanisms contributing 
to the development of peripheral neuropathy. Several treatment options exist; however, few 
target the underlying pathophysiology implicated in painful diabetic neuropathy. Treatments 
aimed at alleviating the symptoms associated with painful neuropathy are either insufficient at 
managing the pain or come with significant risk of side effects. Current treatment algorithms 
recommend use of oral pharmacologic therapies as first line treatment options for the 
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management of symptoms; however, none of these medications target the underlying pathologies 
thought to contribute to the development of painful diabetic neuropathy, highlighting the need to 
develop pathogenetic treatment options for painful diabetic neuropathy as well as other 
neuropathic pain conditions [9, 17, 33].  
Pathogenetic Treatment  
Although current therapeutic options do not address the underlying mechanisms driving 
painful diabetic neuropathy, several therapies under development are showing significant 
promise in both cell culture and animal models. One treatment option currently licensed for use 
in Japan and India is Epalrestat, an aldose reductase inhibitor (ARI). Aldose reductase is an 
enzyme responsible for converting glucose into sorbitol, the first step in the polyol pathway, and 
accumulations in sorbitol lead to intracellular osmotic stress which is thought to play a role in 
nerve damage [30]. Aldose reductase inhibitors have shown some benefit for decreasing pain 
associated with diabetic neuropathy, however, clinical improvement was not particularly 
convincing [17, 30]. 
Use of antioxidants has been evaluated based on the theory that oxidative stress, 
particularly lipid peroxidation and free radical production, may contribute to the pathology of 
diabetic neuropathy. This occurs as a consequence of damage to mitochondria as well as 
inhibition of the vasodilatory effects of nitric oxide, leading to neuronal ischemia and nutrient 
deprivation. Several countries have approved the use of the antioxidant α-lipoic acid for 
treatment of painful neuropathy, and two studies (the ALADIN III study, and the SYDNEY 2 
Trial) have shown a significant reduction in pain, paresthesias and numbness following 
intravenous or oral administration of α-lipoic acid, although no improvement in clinical 
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measurements was seen [34-36]. Another antioxidant, acetyl-L-carnitine, showed a reduction in 
pain and improvement in vibratory sensation; however, no improvements were seen in nerve 
conduction velocities [34, 37]. Finally, benfotiamine, a vitamin B1 derivative, showed promising 
results in a phase III clinical trial, notably improving pain sensation [38]. Collectively, the 
positive outcomes seen in response to treatment with antioxidants suggests that oxidative stress 
plays a major role in the development of diabetic neuropathy, and that these compounds could be 
used as adjunct therapy to minimize pain in patients suffering from painful diabetic neuropathy.   
Other pathophysiological treatment options under investigation include the protein kinase 
C-β (PKC-β) inhibitor, Ruboxistaurin, which, despite promising phase II results, did not have 
favorable phase III outcomes [39]. C-peptide is part of the pro-form of insulin, and binds to and 
activates a G-protein couple receptor (GPCR) that leads to activation of phospholipase C (PLC), 
which in turn leads to increased intracellular calcium levels and activation of endothelial cell 
nitric oxide synthase (eNOS) and PKC. Activation of PKC, in combination with dacylglycerol 
(DAG) synthesis, promotes activation of Na+/K+ ATPase which improves vascular functioning 
and nerve conduction velocities. As such, C-peptide replacement therapy has received attention 
for its potential to improve nerve fiber function (both C-fibers and myelinated fibers) in patients 
with diabetes [17, 40]. C-peptide, therefore, is ultimately thought to improve nerve conduction in 
the small-fibers affected by painful diabetic neuropathy. 
Symptomatic Treatment 
The treatment of painful diabetic neuropathy is centered around the use of 
pharmacological agents, such as tricyclic antidepressants (TCAs), selective serotonin and 
norepinephrine reuptake inhibitors (SNRIs), anticonvulsants, and opioids. Currently, there are 
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only two agents approved by the FDA for the treatment of painful diabetic neuropathy- 
duloxetine (SNRI) and pregabalin (anticonvulsant), while others are primarily used off-label 
[17]. Antidepressants have long been used in the treatment of neuropathic pain, and both TCAs 
and SNRIs are considered first-line treatment options for mitigating pain [33]. Use of TCAs has 
waned recently in favor of newer drugs that have fewer side effect profiles, such as SNRIs [20, 
27, 35]. Some of the first pharmaceuticals developed for the treatment of mood disorders were 
the TCA’s, and this class of antidepressants are some of the best studied in terms of their efficacy 
for treating neuropathic pain. This class of drugs works by inhibiting the re-uptake of serotonin 
and norepinephrine, effectively increasing the concentration of these neurotransmitters in the 
nerve synapse. Amitryptiline, nortriptyline, imipramine and desipramine are the most commonly 
used TCA’s for treating painful diabetic neuropathy. Although efficacious, these drugs come 
with significant risk of side effects such as weight gain, orthostatic hypotension, cardiac 
arrhythmias, dry mouth, constipation and somnolence among others. However, these drugs are 
relatively inexpensive and side effects can be minimized through step-wise increases in effective 
doses [9, 34, 41, 42]. More recently, the selective serotonin and norepinephrine reuptake 
inhibitors (SNRIs), such as duloxetine and venlafaxine, have shown beneficial outcomes in 
reducing perceived pain in patients with painful neuropathy. The major side effects of SNRIs are 
nausea, drowsiness, constipation, dry mouth and a decreased appetite [34, 41].   
 Gabapentin and pregabalin are primarily used as anticonvulsants. These medications are 
calcium channel modulators and work by binding to the α2δ-subunit of voltage-gated calcium 
channels, thereby preventing neurotransmitter release. Structurally, gabapentin resembles the 
neurotransmitter γ-aminobutyric acid (GABA) which is the main inhibitory neurotransmitter in 
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the central nervous system. Gabapentin has been shown to be effective at reducing neuropathic 
pain in patients with diabetes compared to placebo, as well as reporting improvements in sleep. 
However, extremely high doses of gabapentin (up to 3600 mg per day) were needed to achieve 
efficacy [9, 33, 43]. Pregabalin is a stronger α2δ-subunit agonist and, therefore, requires much 
lower doses (300-600 mg per day) to achieve maximum benefit. Pregabalin was effective at 
reducing mean pain scores in patients with painful diabetic neuropathy; however, there was no 
improvement in nerve conduction studies [44]. Side effects of both include sedation, dizziness, 
peripheral edema, headache and weight gain. Both gabapentin and pregabalin are considered 
first-line treatment options for painful diabetic neuropathy, and pregabalin is one of two drugs 
approved by the FDA specifically for the treatment of painful diabetic neuropathy [9, 33, 41].  
 Opioids are commonly used for alleviating pain that can result from a variety of 
situations. In the case of painful diabetic neuropathy, tramadol, a weak µ-opioid receptor agonist, 
and controlled release oxycodone, a strong µ-opioid receptor agonist, have been shown to be 
successful in reducing pain. Caution is advised when prescribing opioids due to their high side 
effect profile which includes sedation and respiratory dysfunction, drug dependency risk, abuse 
and misuse potential, changes to the immune system after prolonged use, and decreasing efficacy 
over time. It is recommended that opioids be reserved for patients who are refractory to first line 
treatment, or who are suffering from acute exacerbations of neuropathic pain. Combination 
therapy using gabapentin and morphine showed synergistic effects using lower doses of each 
medication, and may provide an alternative line of treatment [33, 34, 41, 42]. 
 Several other drugs within each of the aforementioned treatment categories have been 
evaluated but show less efficacy or inconsistent results to be considered mainstays for the 
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treatment of painful diabetic neuropathy. Additionally, most pharmacological agents carry risk of 
systemic adverse events. As such, topical delivery of therapeutic agents has been suggested as a 
potential treatment modality to alleviate symptoms of painful diabetic neuropathy [45]. Repeated 
application of 0.05-0.075% capsaicin cream, which effectively depletes the pain-inducing 
neuropeptide substance P, along with other pro-nociceptive molecules, from cutaneous 
peripheral nerve endings has mixed outcomes. Recently, use of a single high-dose (8%) 
capsaicin patch has shown promising results in post-herpetic neuralgia (PHN) and human 
immunodeficiency virus (HIV)-induced neuropathy  [33, 34, 41, 46, 47]. Topical lidocaine 
decreases the excitability of cutaneous Aδ- and C-fibers, and has been effective at reducing pain 
associated with PHN and painful diabetic neuropathy. In a 4-week head-to-head study, 5% 
topical lidocaine plaster was shown to produce results similar to pregabalin at reducing pain and 
improving quality of life in patients with painful diabetic neuropathy [48].  
 Despite the numerous aforementioned treatment options for painful diabetic neuropathy, 
these methods are insufficient for the-long term management of pain symptoms. This highlights 
the need for the development of new approaches that treat the underlying pathophysiology of 
painful diabetic neuropathy, rather than generalized symptomatic treatment. Development of 
novel treatment modalities that activate endogenous antinociceptive pathways, such as that 
proposed in this dissertation, would provide an efficacious alternative for the treatment of painful 
diabetic neuropathy.  
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Nociception: From the Periphery to the Central Nervous System 
Pain Sensation  
Pain is a complex sensation that involves many types of neurons, receptors and 
neurotransmitters that are responsible for translating sensory information from the periphery into 
electrical impulses that are processed by the central nervous system. The International 
Association for the Study of Pain (IASP) defines pain as, “an unpleasant sensory and emotional 
experience associated with actual or potential tissue damage, or described in terms of such 
damage.” Pain is the body’s natural warning system and is usually protective in nature. However, 
when pain is no longer beneficial, the transition from ‘good’ pain to ‘bad’ pain can become 
particularly disabling and destructive to a person’s quality of life, as is the case with painful 
diabetic neuropathy.  This multifaceted change likely involves several mechanisms operating at 
multiple levels of nociceptive processing.  
Acute pain is beneficial in that it keeps one from causing serious injury to themselves, or 
from continuously re-injuring areas that are already damaged. Evidence of the benefit of pain is 
seen in individuals who cannot sense when they are in danger and consequently injure 
themselves frequently. Tissue damage leads to the production and release of a host of 
inflammatory and algesic mediators, such as substance P, prostaglandins, leukotrienes and 
histamine, resulting in heightened sensitivity of the tissue or area surrounding the wound. 
Importantly, acute pain usually subsides once the wound has healed. Pathological pain, on the 
other hand, is pain that has persisted beyond its beneficial stage. Pathological pain is typically 
chronic in nature (lasting > 3 months), and can persist in the absence of any identifiable trauma 
or lesion [49, 50].  
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The IASP defines neuropathic pain as “pain caused by a lesion or disease of the 
somatosensory nervous system.” Painful diabetic neuropathy is a type of neuropathic pain that 
involves the peripheral nervous system, and is a type of chronic pathological pain. There are 
several sites along the neuroaxis where alterations in nociceptive signaling can lead to 
neuropathic pain, including damage or sensitization at peripheral, spinal or supraspinal sites. 
Peripherally, nerve injury can lead to neuroma formation which can generate spontaneous 
activity or elicit sensitization to stimuli. Intact peripheral nerves may also emit spontaneous 
activity, often due to increased expression or sensitization of the channels they express. Channel 
sensitization can occur through a decrease in the threshold for activation, or by larger responses 
to stimulus input. Central sensitization occurs within the spinal cord, primarily in the dorsal horn 
where peripheral pain sensing neurons terminate, and can arise from inflammation, altered 
release of neurotransmitters (both excitatory and inhibitory), and altered input to spinal 
interneurons (ex: disinhibition of inhibitory interneurons) [51].  
Pain Transmission 
Pain is conveyed from the periphery by specialized nerves termed nociceptors. These 
nerves contain channels and receptors that detect and respond to specific types of noxious 
stimuli, primarily thermal, mechanical, and/or chemical stimuli. Nociceptors require a stimulus 
of sufficient intensity for activation, and this minimum threshold for activation can change under 
pathological conditions. The majority of nociceptors are categorized as thinly myelinated Aδ-
fibers, or unmyelinated c-fibers. The cell bodies of these neurons are located in structures called 
dorsal root ganglia (DRG) that are located next to the spinal column (Fig. 1). These neurons have   
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Figure 1. Fiber types involved in conveying sensory information from the periphery to the 
central nervous system. The cell bodies of peripheral sensory nerves are located adjacent to the 
spinal column in structures called dorsal root ganglia. Several fiber types are responsible for 
conveying sensory information from the periphery to the central nervous system. Aβ-fibers are 
the largest fiber type and are wrapped in a thick myelin sheath, which allows for extremely rapid 
conduction of action potentials along the length of the axon. These neurons are primarily 
responsible for non-noxious stimuli such as light touch, pressure, and proprioception. Aδ-fibers 
are thinly myelinated fibers that, together with the unmyelinated C-fibers, are primarily 
responsible for conveying noxious stimuli from the periphery. Some Aδ- and C-fibers are 
polymodal nociceptors and can convey noxious thermal, mechanical and chemical stimuli. Each 
of these different fibers terminates in a characteristic lamina in the dorsal horn of the spinal cord. 
Aβ-fibers terminate in deep in the dorsal horn, in laminae III, IV and V. Aδ-fibers terminate in 
laminae I and V, whereas C-fibers terminate in lamina I and outer lamina II (peptidergic), and 
the inner part of lamina II (nonpeptidergic). This figure was modified from Basbaum et al., 2009 
[49]. 
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a single axon that splits into two branches: the peripheral branch, which innervates target tissues 
in the periphery (ex. skin, muscle), and the central branch, which enters the central nervous 
system where it synapses with second order neurons in the dorsal horn of the spinal cord. In the 
mouse, peripheral branches of neurons emanating from lumbar DRG’s terminate in the hind paw, 
and the associated central branches terminate in the medial portion of the dorsal horn [49, 50].  
Fiber types involved in pain transmission 
There are three main fiber types involved in the transduction of sensory information from 
the periphery into electrical signals that the body can process. Aβ-fibers are the largest fibers and 
are surrounded by a thick myelin sheath that allows them to rapidly conduct information. These 
fibers are primarily responsible for conveying non-noxious stimuli, such as touch and muscle 
movement. Although these fibers are not directly involved in pain transmission, there is evidence 
to suggest that following nerve damage these fibers can undergo a phenotypic switch where they 
begin to express substance P, a known pro-inflammatory molecule involved in pain transmission 
and sensation [52]. Activation of these fibers leads to substance P release, contributing to 
transmission of nociception in the periphery [53]. Additionally, under pathological conditions 
there is evidence to suggest that Aβ-fibers can sprout into the dorsal horn, placing them in close 
proximity to peripheral pain sensing neurons [52]. As such, Aβ-fibers can be activated following 
activation of nociceptors, and thus can contribute to pain transmission.  
Aδ-fibers are small-diameter, thinly myelinated fibers that are involved in conveying pain 
sensation from the periphery. These fibers can be further subdivided into either type I or type II 
fibers. Type I Aδ-fibers have a high heat threshold, but low mechanical and chemical thresholds. 
Following tissue injury, type I Aδ-fibers have been shown to sensitize, lowering their heat and 
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mechanical thresholds. Type II Aδ-fibers have a high mechanical and chemical threshold, but 
have a relatively low heat threshold. Because of these different thresholds within the Aδ-fiber 
population, it is believed that these fiber types convey different information when responding to 
a stimulus: type I fibers are presumed to convey acute responses to intense mechanical and 
chemical stimuli, whereas type II fibers are thought to convey acute thermal information [49]. 
C-fibers are small-diameter, unmyelinated neurons also involved in pain sensation and 
transmission. Some C-fibers are polymodal in that they can detect both thermal and mechanical 
stimuli. C-fibers can be further subdivided into either peptidergic or nonpeptidergic fibers. 
Peptidergic fibers release the pro-nociceptive neuropeptides substance P and calcitonin gene-
related peptide (CGRP), as well as express the TrkA receptor that responds to neurotrophic 
growth factor (NGF). Nonpeptidergic neurons express the receptor c-Ret, which responds to 
glial-derived neurotrophic factor (GDNF), neurturin and aretemin. Nonpeptidergic neurons also 
express the markers isolectin B4 (IB4), the GPCR Mrgprd, and the P2X3 receptor. [49, 50, 54] 
Each of these fiber types (Aβ-, Aδ- and C-fibers) have central projections that terminate 
in the dorsal horn of the spinal cord. The dorsal horn is divided into several different laminae 
based on where certain fiber types terminate (see Fig. 1). The outermost region is often referred 
to as the substantia gelatinosa, and this is where most peripheral nociceptors terminate. Aδ-fibers 
primarily project to lamina I as well as deeper into lamina V, and C-fibers project to laminae I 
and II. C-fiber projection patterns can be further subdivided, with peptidergic neurons 
predominantly localized to lamina I and the outer portions of lamina II, and nonpeptidergic fibers 
found in the middle regions of lamina II. Aβ-fibers terminate in the deeper layers of the dorsal 
spinal cord, projecting to laminae III, IV and V. [49, 50] 
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Pain and heat information is transmitted up the spinal cord to higher processing centers 
through the spinothalamic tract [55]. Information from Aδ- and C-fibers is passed to second 
order neurons via spinal interneurons. These second order neurons then cross the midline of the 
spinal cord and ascend through the spinothalamic tract where they synapse in the ventroposterior 
lateral nucleus of the thalamus. Tertiary neurons project out to the cortex where information is 
processed and integrated, and a reaction occurs in a protective maneuver to prevent further injury 
or harm from occurring.  
Channels involved in pain transmission    
 Nociceptors contain many channels that are responsible for detecting and transmitting 
noxious stimuli, and most have a high threshold for activation thus allowing them to detect 
harmful stimuli. Recent progress has identified specific channels that transmit heat, cold, 
mechanical and chemical stimuli, but precise assignment of channels to the detection of 
individual modalities remains complicated. Studies using cell culture and transgenic mice have 
aided in this discovery, albeit with mixed results. Additionally, there are a variety of channels 
involved in modulating nerve conduction and regulating neurotransmitter release that also 
contribute to the detection of environmental stimuli. Furthermore, environmental factors and 
inflammatory mediators can modulate sensory neuron signaling, adding to the complexity of 
transmitting nociceptive signals. 
Thermosensation 
Heat transduction: Sensory neurons are capable of distinguishing between general 
warmth and noxious heat, which has been reported as 43°C, with temperatures above this 
threshold perceived as potentially damaging to tissues. Capsaicin, the chemical responsible for 
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the burning sensation felt in response to eating a hot chili, signals through a member of the 
transient receptor potential (TRP) ion channel family of the vanilloid 1 subtype (TRPV1). 
TRPV1 is a non-selective ligand-gated ion channel primarily expressed on small-diameter 
neurons in the DRG that is highly permeable to calcium cations [56]. TRPV1 null mice display 
an impaired ability to detect noxious heat [57], linking TRPV1 activity to thermosensation. 
Subsequent studies have provided further evidence that TRPV1 is involved in mediating 
inflammation-induced thermosensitivity [58]. Other members of the TRP family have also been 
suggested to play a role in heat sensation, including TRPV2 (threshold for activation ~52°C), 
TRPV3 and TRPV4 (thresholds between 25°C and 35°C). [49] 
Cold transduction: Another member of the melastatin family of TRP channels, TRPM8, 
is responsive to cold temperatures and methanol, a natural cooling agent, with a threshold of 
activation around 25°C [59]. TRPM8 is also a ligand-gated cation channel primarily expressed 
on a subset of nociceptive neurons, distinct from neurons that express TRPV1. TRPM8 null mice 
display altered sensitivity to cold over a range of temperature from 30°C to 10°C, but display 
normal responses to noxious heat [60, 61]. Detection of intense, noxious cold (<15°C) is 
proposed to occur through a member of the ankyrin family of TRP channels, TRPA1, but this is 
still controversial based on the behavioral responses of knockout mice [62, 63]. Additionally, 
mice lacking the sodium channel Nav1.8 show altered response to cold over a range of 
temperatures [49, 64]. 
Mechanosensation  
Somatosensory detection of mechanical stimuli ranges from light brushing to damaging 
noxious stimuli. Aβ-fibers, which have a low threshold of activation for mechanosensation, 
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detect light touch/pressure and vibration through innervations with Pacinian corpuscles, Merkel 
cells, and hair follicles present in the skin. In contrast, Aδ- and C-fibers, which terminate in the 
dermis and epidermis, respectively, have a high threshold for detecting mechanical stimuli, and 
thus serve to detect noxious mechanical stimuli. However, identification of specific channels 
responsible for transducing mechanical sensation remains largely undetermined. Several 
candidate receptors have been identified, including members from the TRP family (TRPV4, 
TRPA1) as well as certain acid sensing ion channels (ASICs; ASIC1, ASIC2, ASIC3). TRPV4 is 
expressed on small- and large-diameter cells in the DRG, and has been shown to co-localize with 
a variety of cell types in the skin. Interestingly, TRPV4 is not expressed in the spinal cord, 
suggesting a peripheral mechanism of action for this putative mechanotransducer [65]. Use of 
animal models to discern the mechanotransduction properties of channels has provided mixed 
results, as detection of mechanosensation at a cellular level remains difficult. Theories pertaining 
to the gating of channels involved in transducing mechanical stimuli have been proposed, 
including stretch-sensitive channels that open in response to deformations in the membrane 
bilayer, direct gating resulting from the tethering of mechanosensitive channels to the cellular 
cytoskeleton or extracellular matrix, or indirect gating through activation of and modulation by 
signaling intermediates [66].   
Chemical Sensation 
Chemical sensation involves the detection of irritants, such as endogenous factors that are 
released following injury and environmental chemicals that activate receptors on nociceptive 
neurons. Several members of the ‘inflammatory soup’ contribute to chemical sensation, such as 
protons, ATP, histamine, prostaglandins, bradykinin, substance P and adenosine. Many members 
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of the TRP family of ion channels detect a variety of chemical irritants, and TRPA1 knockout 
mice show decreased sensitivity to some chemical irritants. [49] 
Receptors involved in nociception can be broadly categorized into either metabotropic or 
ionotropic receptors. Metabotropic receptors involve second messenger signaling cascades, and 
include the class of receptors called G-protein coupled receptors (GPCR’s). GPCR’s 
characteristically have seven transmembrane domains and an associated heterotrimeric G-protein 
comprised of three separate subunits: an α-subunit, a β-subunit, and a γ-subunit. Binding of a 
ligand to the receptor causes a conformational change, which in turn activates the G-protein 
causing it to dissociate from the receptor. Once activated, the α-subunit dissociates from the βγ-
subunit, and both can then go on to activate downstream second messengers that propagate the 
initial signal. Ionotropic receptors primarily form pores through a cell membrane that, upon 
ligand binding, can open to allow the movement of molecules from one side of the cell to the 
other, typically following a concentration gradient.   
 
Purinergic Signaling and Nociception 
 Purinergic signaling, by definition, involves signaling mediated by purine nucleotides and 
nucleosides, such as adenosine and adenosine triphosphate (ATP) [67]. The concept of 
purinergic signaling was first proposed in the 1970’s based on the observation that ATP could 
act as a transmitter in both the central and peripheral nervous systems. It is now recognized that 
ATP can act as both a neurotransmitter and as a source of energy for cellular processes. 
Identification of adenosine (P1) and ATP (P2) receptors has led to an explosion of interest in 
purinergic signaling, particularly in the setting of disease, and the potential of these signaling 
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pathways for modulating disease pathology. Extracellular ATP is rapidly degraded by 
specialized enzymes termed ectonucleotidases (see discussion below) that terminate ATP-
induced pro-nociceptive signaling, and also generate intermediate hydrolysis products, such as 
adenosine diphosphate (ADP) and adenosine monophosphate (AMP), which in turn can activate 
additional P2 receptors (Fig. 2). 
ATP-mediated Signaling  
ATP is stored intracellularly at concentrations around 2-5 mM, and concentrations in 
synaptic vesicles can be as high as 100 mM. ATP release in neurons is presumed to occur 
through the fusion of synaptic vesicles at nerve terminals (alone or in combination with other 
neurotransmitters such as acetylcholine, CGRP and substance P, dopamine, GABA or glutamate, 
and release can occur in response to exercise, mechanical deformation, osmotic swelling, 
ischemia or from damaged and dying cells. Thus, ATP signaling has been shown to be involved 
in a variety of physiological processes such as synaptic transmission, platelet aggregation, 
immune modulation, cell proliferation, migration and differentiation, and pain signaling [67]. 
Purinergic signaling has also been implicated in a variety of pathological conditions, especially 
in the central nervous system (CNS). Altered purinergic signaling is seen following CNS trauma 
and cerebral ischemia; in neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s 
disease, Huntington’s disease, multiple sclerosis, and diabetes; in seizure disorders and migraine; 
in depression and anxiety, including the adenosine-mediated antidepressive effects of some 
medications (ex: TCAs, SNRIs); and, relevant to this body of work, in neuropathic pain. [68] 
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Figure 2. Overview of purinergic signaling. Adenosine and ATP are synthesized 
intracellularly, and then released into the extracellular space following tissue damage or injury, 
or through nucleotide transporters present in the cell membrane. Once released, nucleotides can 
activate the P2 family of receptors: the ionotropic P2X and metabotropic P2Y receptors. 
Alternatively, nucleotides can by hydrolyzed by ectonucleotidases, specialized enzymes that 
have their catalytic domain oriented towards the outside of the cell. In the case of ATP, 
hydrolysis by ectonucleotidases results in the production of adenosine, which can then go on to 
activate the P1 family of receptors, also known as the adenosine receptor family. This figure was 
modified from Roman and Fitz, 1999 [69].  
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ATP acts on P2 receptors, which are further subdivided into ionotropic P2X or 
metabotropic P2Y receptors. There are currently seven recognized P2X receptors (P2X1-7), and 
all are ligand-gated ion channels that are activated by ATP. P2X channels are highly permeable 
to Ca2+, and to a lesser extent K+ and Na+. P2X subunits have two transmembrane domains, with 
the NH2- and COOH-termini of these receptors located intracellularly, and P2X channels are 
presumed to form through the assembly of three or four subunits [70]. All P2X receptor subtypes 
have been detected in sensory neurons, and many studies have documented their role in pain 
transmission. In the DRG, P2X3 shows the highest expression, and is primarily expressed on 
IB4+ nonpeptidergic neurons. P2X4 has been linked to mechanical allodynia following nerve 
injury, and expression of P2X4 is markedly up-regulated in activated microglia in the dorsal horn 
of L5 nerve injured rats [71]. Furthermore, blockade of this receptor using pharmacological 
antagonists reversed the nerve injury-induced mechanical allodynia. [71]  
There are eight recognized P2Y receptors (P2Y1, P2Y2, PY24, P2Y6, P2Y11, P2Y12, 
P2Y13 and P2Y14). All are GPCRs and have their NH2-terminus domain located on the 
extracellular side of the membrane, while the COOH-terminus is located intracellularly. P2Y 
receptors can be subdivided based on the G-protein associated with each receptor.  P2Y1, P2Y2, 
PY24, and P2Y6 are associated with Gq/11;  P2Y11, can couple with both Gq/11 and Gs; P2Y12 and 
P2Y13 couple to Gi; and P2Y14 is coupled to Gi/o. Alternatively, the P2Y receptors can be 
classified based on the ligand for activation: P2Y1 preferentially responds to ADP over ATP; 
P2Y2 and P2Y4 receptors are equally activated by ATP and UTP; P2Y6 receptors are selectively 
activated by UDP; P2Y12 and P2Y13 are preferentially activated by ADP; and P2Y14 is 
selectively activated by UDP-glucose. [72]. P2Y receptors are expressed on small-, medium- and 
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large-diameter neurons in the DRG. Recently, P2Y12 was suggested to play a role in pain 
signaling. P2Y12 expression was shown to be upregulated in activated microglia following nerve 
injury in rats [73], and studies using antagonists to P2Y12 showed diminished development of 
neuropathic pain following spinal nerve injury [74] or spared nerve injury models of neuropathic 
pain [73] in mice and rats, respectively.  
Integrating information related to altered purinergic signaling and its contribution to the 
development of neuropathic pain has made great strides in recent years. Following nerve injury, 
ATP and other nucleotides are released from damaged and dying cells leading to activation of 
sensory neurons that contain ATP-sensitive receptors, such as those found on Aδ- and C-fibers, 
and this increases nociception, nociceptor sensitization, and neuropathic pain. In diabetic 
neuropathy, changes in neuronal support in the setting of chronic hyperglycemia and 
inflammation underlie mechanisms that contribute to the ‘dying-back’ neurodegenerative 
phenotype. Upregulation of pro-nociceptive receptors, such as P2X3, P2X4, P2X7 and P2Y12 
have been shown to be involved in neuropathic pain models, and could contribute to the 
development of painful diabetic neuropathy, especially given the likelihood of increased ATP 
present to activate these receptors.  
Adenosine Signaling and Receptor Activation 
Extracellular adenosine comes from two main sources: release of intracellular stores 
through membrane-bound channels called equilibrative nucleotide transporters (ENTs), or 
through extracellular hydrolysis of adenine nucleotides by ectonucleotidases. Unlike ATP, 
adenosine is not stored in or released from synaptic vesicles. Basal physiological levels of 
extracellular adenosine are estimated to range from 30-200 nM [75]. Once released, adenosine 
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can modulate neuronal signaling presynaptically through inhibition or facilitation of transmitter 
release, or postsynaptically by causing hyperpolarization or depolarization of postsynaptic 
neurons, owing to the observation that adenosine receptors are found on both pre- and post-
synaptic nerve terminals. Additionally, adenosine levels can be modulated through inhibition of 
adenosine kinase (preventing the conversion of adenosine into AMP) or adenosine deaminase 
(preventing the deamination of adenosine into inosine), or through inhibition of ENTs, 
effectively increasing the level of extracellular adenosine allowing for increased activation of 
adenosine receptors. [76, 77] 
Adenosine acts on the P1 class of receptors (adenosine receptors), with downstream 
effects dependent on the specific receptor subtype activated (Fig. 3). There are currently four 
recognized adenosine receptors (A1, A2A, A2B and A3), all of which are GPCR’s. The adenosine 
A1 receptor (A1R) and the adenosine A3 receptor (A3R) are Gi/o-coupled receptors and activation 
results in inhibition of adenylyl cyclase with subsequent decreases in 3’,5’-cyclic adenosine 
monophosphate (cAMP) production, whereas the adenosine A2A receptor (A2AR) and the 
adenosine A2B receptor (A2BR) are Gs-coupled receptors, which stimulate adenylyl cyclase 
activity and increase cAMP production. Most of the literature thus far has focused on the 
seemingly antagonistic actions of A1R and A2AR, with much less known about A2BR and A3R.  
 The A1R is highly expressed in the central nervous system, including the cortex, 
cerebellum and hippocampus, as well as in the dorsal horn of the spinal cord. In the DRG, A1R 
is located on small- and medium-diameter neurons, and is found both pre- and post-synaptically 
as well as on interneurons. Adenosine can act in a manner similar to that of the major inhibitory 
neurotransmitter, GABA, in that activation of A1R leads to suppression of excitatory signaling   
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Figure 3. Signaling downstream of A1R. A1R is a GPCR, and activation of A1R results in 
inhibition of adenylyl cyclase, with subsequent inhibition of cAMP production, via activation of 
the Gαi subunit of the associated heterotrimeric g-protein. Activation of the βγ-subunit of the 
heterotrimeric g-protein results in inhibition of P-, Q- and N-type Ca2+ channels, as well as 
activation of PLC. PLC activation results in cleavage of PIP2 into DAG and IP3. PIP2 has been 
shown to modulate TRPV1 signaling, and cleavage of PIP2 results in decreased calcium flux 
through TRPV1. Abbreviations: GPCR—G-protein coupled receptors; cAMP 3’,5’-cyclic 
adenosine monophosphate; PLC—phospholipase C; PIP2—phosphatidylinositol 4,5-
bisphosphate; DAG—diacylglycerol; IP3—inositol 1,4,5-triphosphate; TRPV1—transient 
receptor potential vanilloid 1 type. This figure was modified from Jacobson et al., 2009 [78]. 
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molecules such as glutamate, acetylcholine and dopamine through decreased calcium influx [76, 
79, 80], and thus is attributed with antinociceptive effects. Activation of A1R not only inhibits 
adenylyl cyclase, but it can also activate phospholipase C (PLC) resulting in cleavage of 
phosphatidylinositol bisphosphate (PIP2) and concurrent generation of diacylglycerol (DAG) and 
inositol 1,4,5-triphosphate (IP3). Additionally, activation of A1R is associated with inhibition of 
P-, Q- and N-type Ca2+ channels, and activation of potassium (K+) channels. [77]  
A2AR is predominantly located on GABAergic striatopallidal neurons in the cortex, as 
well as in immune tissues such as the spleen, thymus and on leukocytes. Activation of this 
receptor results in activation of adenylyl cyclase, resulting in increased cAMP levels, and can 
also promote release of neurotransmitters such as glutamate, leading to increased excitatory 
signaling. As such, activation of A2AR is attributed with increased pain sensation. A2BR shows 
low levels of expression in many different tissues, including neuronal tissues such as the brain 
and spinal cord. Activation of A2BR is associated with activation of adenylyl cyclase and 
increased cAMP levels, as well as activation of PLC, but this receptor has a low affinity for the 
endogenous ligand adenosine. A3R is found primarily in peripheral tissues and has been shown 
to be expressed on glial cells and neurons. A3R is linked to inhibition of adenylyl cyclase and 
activation of PLC. [80] 
Adenosine receptors have been the target of a variety of therapeutic interventions, and 
several agonists and antagonists have been identified to pharmacologically manipulate activation 
or inhibition of adenosine receptors, respectively. Use of these selective agonists and antagonists 
has aided in the discovery signaling pathways that may be affected following injury to the 
nervous system, allowing for the development of novel therapeutics that could be used to 
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improve clinical outcomes. Agonists selective for A1R have been generated through substitution 
at specific sites in the adenine nucleoside. For example, substitution at the N6-position lead to the 
creation of N6-cyclopentyladenosine (CPA), a highly selective and potent A1R agonist. Further 
modification of this structure with chlorine lead to the development of a slightly more potent 
agonist, 2-chloro-CPA (CCPA). Caffeine and xanthine moieties, such as theophylline, are 
nonselective adenosine receptor antagonists. Modification of xanthines has led to the 
development of selective adenosine receptor antagonists, such as 8-cyclopentyl-1,3-
dipropylxanthine (DPCPX), selective for A1R [81, 82]. Interestingly, caffeine antagonizes both 
A1R and A2AR, and the stimulatory effects of caffeine have recently been shown to be mediated 
through A2AR [83].  
Peripherally, activation of the adenosine receptor has numerous effects on the 
cardiovascular system. Intravenous (i.v.) infusion of adenosine lowers heart rate and atrial 
contractility and is used to treat patients with paroxysmal supraventricular tachycardia, but 
caution is advised as this has been associated with the development of hypotension. Adenosine is 
released following ischemia, and activation of A1R following myocardial infarction may prove 
to be beneficial to cardiomyoctes by diminishing ischemia-reperfusion induced injury [84, 85]. 
In the central nervous system, activation of A1R is associated with inhibition of nociceptive 
signaling, presumably through inhibition of glutamate release from spinal interneurons. Indeed, 
mice lacking A1R (A1R-/-) show increased nociceptive responses to heat in the tail flick assay 
and following carrageenan-induced inflammatory pain.  Following intrathecal (i.t.) 
administration of the A1R agonist, N6-(R-phenylisopropyl)adenosine (R-PIA), A1R-/- mice 
showed blunted recovery in thermal hyperalgesia compared to WT mice, suggesting that 
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analgesic adenosine analogues exert their antinociceptive effects through centrally located A1R’s 
[79, 86].  
Although animal models showing the beneficial antinociceptive effects of adenosine 
seem promising, translating the immense amount of knowledge into therapies for human 
neuropathic pain has remained challenging. Human studies investigating adenosine as a potential 
analgesic have shown limited efficacy. In a small-scale tolerability study, patients receiving i.t. 
adenosine (500 µg or 1000 µg) reported decreased spontaneous and evoked pain during infusion, 
as well as increased withdrawal thresholds to mechanical stimuli. Transient low back pain was 
reported in a few patients, but this resolved within 30 min following administration of adenosine 
[87]; headache has also been reported following i.t. adenosine [88]. In a larger placebo-
controlled study, systemic (i.v.) infusion of adenosine (40-50 µg/kg/min for 60 min) resulted in 
increased tactile pain thresholds as well as patient-reported improvements in overall general pain 
sensation. Interestingly, three patients reported improvement in pain symptoms for several hours, 
and two patients reported complete pain relief for over six months [89]. Another study 
comparing the efficacy of i.t. versus i.v. adenosine found that i.t., but not i.v., adenosine 
decreased the area of allodynia and reduced evoked pain in response to mechanical stimuli, but 
that neither were effective in reducing ongoing or spontaneous pain [88].  
 
Ectonucleotidases 
 As mentioned previously, one of the major sources of extracellular adenosine is through 
hydrolysis of extracellular ATP by specialized enzymes termed ectonucleotidases. 
Ectonucleotidases belong to a class of ecto-enzymes, which have their catalytic domain oriented 
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towards the outside of the cell. Studies investigating the role of ecto-enzymes in physiological 
processes has made significant strides over the last few decades as the technologies for analysis 
have developed. These enzymes regulate diverse physiological processes, acting to mitigate 
ATP-induced pro-nociceptive signaling by hydrolyzing ATP into the analgesic small molecule 
adenosine (Fig. 4). The role of ectonucleotidases in pain signaling, specifically related to 
termination of pro-nociceptive signaling through hydrolysis of ATP, has gained attention in 
recent years. Though the contribution of ectonucleotidases to the development of painful diabetic 
neuropathy remains largely unknown, two specific ectonucleotidases (discussed in detail below), 
have been shown to mediate antinociceptive signaling in inflammatory and neuropathic pain 
conditions.  
Generation of adenosine is accomplished by the step-wise degradation of ATP by specific 
ectonucleotidases. Ectonucleoside triphosphate diphosphohydrolases (E-NTPDases; CD39 
family) hydrolyze nucleotide triphosphates, such as ATP, and nucleotide diphosphates, such as 
ADP, into AMP by cleaving phosphodiesterase bonds. E-NTPDases have short N- and C-
terminal domains, two transmembrane domains, and a large extracellular glycosylated catalytic 
domain. The molecular mass of this protein is predicted around 70-80 kDa. There are eight 
recognized E-NTPDases, and four have been shown to be expressed on the cell surface 
(NPTDase1, 2, 3 and 8) [90, 91]. NTPDase1 (CD39) can be found in vascular endothelium, and 
has been shown to have a role in preventing platelet aggregation by hydrolyzing the potent 
aggregator ADP [92]. Additionally, NTPDase3 has recently been shown to be expressed on  
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Figure 4. Ectonucleotidase mediated hydrolysis of ATP into adenosine. Hydrolysis of 
extracellular ATP is mediated by specialized enzymes called ectonucleotidases. E-NTPDases 
hydrolyze ATP and ADP into AMP. NTPDase3 has been identified in the dorsal horn of the 
spinal cord and the DRG on a similar neuronal population as NT5E and PAP. NT5E are 
responsible for hydrolyzing AMP into adenosine, which can then go on to activate A1R resulting 
in antinociceptive effects.  
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putative nociceptors in the DRG and dorsal horn of the spinal cord, and is associated with NT5E 
expression (see below). Further, NTPDase immunoreactivity was seen in the epidermis of the 
skin, as well as associated with Merkel cells and keratinocytes, suggesting that NTPDases may 
play a role in regulating the peripheral nociceptive environment [93].  
Ecto-5’-nucleotidase (NT5E; CD73 family) hydrolyzes 5’-AMP into adenosine, and this 
is the rate-limiting step in the termination of ATP-mediated signaling. The CD73 family of 
ectonucleotidases are glycophosphatidylinositol (GPI) anchored proteins, and, therefore, do not 
possess any membrane spanning domains. These proteins are also glycosylated and form dimers 
that are held together through non-covalent bonds [94]. Interestingly, NTPDase1 and NT5E are 
highly co-expressed in the brain, which could represent an endogenous physiological mechanism 
to minimize injury resulting from trauma that causes mass release of ATP and other pro-
inflammatory mediators. Moreover, NTPDase1 and NT5E are co-expressed on 
CD4+/CD25+/Foxp3+ T regulatory cells and likely function to inhibit T cell proliferation and 
cytokine secretion by hydrolyzing ATP, and subsequently, AMP into the anti-inflammatory 
mediator adenosine [95, 96].  
There are several well-known examples of ectonucleotidases that perform important 
biological functions, such as cholinesterase which is responsible for terminating cholinergic 
signaling in nerve synapses; enzymes present in the brush borders of the intestines that aid in the 
digestion of food and nutrients; and the angiotensin converting enzyme (ACE) which is the target 
of ACE inhibitors used to treat hypertension [90]. Recent evidence has highlighted the role that 
NT5E and another ectonucleotidase, prostatic acid phosphatase (PAP), play in exerting 
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antinociceptive effects in the setting of neuropathic and inflammatory pain. Akkina et al. 
demonstrated altered enzymatic activity in the dorsal horn of the spinal cord as early as four 
weeks following induction of diabetes [97]. The enzyme thiamine monophosphatase (TMPase) 
hydrolyzes the vitamin B1 derivative thiamine monophosphate (TMP), and, historically, this 
enzyme was used to identify small diameter, nonpeptidergic neurons [98]. However, once IB4 
was identified as an easier-to-use marker of the same neuronal population, use of TMPase as a 
marker of nociceptive neurons faded [99]. Despite the important role this enzyme played in 
anatomical identification of nociceptive neurons, the physiological function of TMPase remained 
largely unknown. It was not until 2008, when TMPase was identified as the membrane bound 
form of PAP [100], that a putative role for this enzyme was put forth.   
PAP has been studied for over 70 years in the prostate cancer field. It was originally 
identified (and is still used) as a serum maker for prostate cancer metastases, but the 
physiological function remained elusive [101]. In 2007, Quintero et al. were the first to identify 
the presence of PAP in tissues other than the prostrate [102]. Two splice variants of PAP were 
identified, a membrane-bound form (TM-PAP) and a secretory form (S-PAP), and TM-PAP was 
found to be highly expressed in the thymus, lung, spleen, kidney, thyroid and salivary gland, and 
to a lesser extent in the brain and prostate. In light of this discovery, Zylka and colleagues set out 
to identify the molecular identity of TMPase.  
Using a series of molecular and genetic techniques and animal models of pain, Zylka et 
al. were able to determine that TMPase was the recently discovered TM-PAP [100]. Transfection 
of HEK293 cells with TM-PAP showed TMPase activity, and genetic deletion of exon 3 in mice, 
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which causes loss of PAP catalytic activity (PAP-/- mice), resulted in a loss of TMPase 
histochemical staining in the DRG and spinal cord. Further characterization of PAP expression in 
the DRG and spinal cord revealed that it is primarily expressed on small-diameter, 
nonpeptidergic neurons, identical to that of TMPase. PAP co-localizes extensively with the 
nonpeptidergic markers IB4, P2X3, and Mrgprd, whereas there is little overlap with TRPV1 and 
CGRP-containing peptidergic neurons [100, 103].  
Given the location of PAP on small-diameter, putative nociceptive neurons, it seemed 
plausible that PAP may play a role in modulating pain sensation. To elucidate the role of PAP in 
nociception, the behavioral responses of PAP-/- mice following complete Freud’s adjuvant 
(CFA)-induced inflammatory pain or the spared nerve injury (SNI) model of neuropathic pain 
were evaluated [100]. PAP-/- mice showed enhanced thermal and mechanical sensitivity in the 
CFA model of inflammatory pain compared to WT mice, whereas only thermal sensitivity was 
exaggerated in the SNI model of neuropathic pain. Surprisingly, a single i.t. injection of purified 
human secretory PAP (hPAP) resulted in long lasting (>3 days) antinociception, causing 
transient improvement of mechanical allodynia and thermal hyperalgesia in both models. 
Furthermore, this effect was eliminated in mice lacking functional A1R (A1R-/- mice), suggesting 
that the antinociceptive effects of hPAP are mediated through activation of A1R, and this is 
dependent on the ability of PAP to hydrolyze extracellular AMP into adenosine.  
Surprisingly, AMP histochemistry in PAP-/- mice did not reveal complete abolishment of 
AMPase activity in the DRG and spinal cord, suggesting the presence of another enzyme in these 
tissues that is also capable of hydrolyzing AMP into adenosine [100]. Subsequent work led to the 
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identification of NT5E as the other primary ectonucleotidase in the DRG and spinal cord that 
hydrolyzes AMP [104, 105]. Expression of NT5E overlapped extensively with PAP, as well as 
IB4, Mrgprd, and P2X3, and again showed little overlap with CGRP and TRPV1, confirming the 
presence of NT5E on small-diameter, nonpeptidergic putative nociceptive neurons. Additionally, 
NT5E, but not PAP, expression was seen in the epidermis of the skin, particularly on Mrgprd + 
neurons and keratinocytes. NT5E-/- mice showed reduced AMPase activity in the DRG and 
spinal cord, with the remaining AMPase activity attributed to PAP activity [104]. 
Similar to PAP-/- mice, NT5E-/- mice showed exaggerated thermal and mechanical 
sensitivity following CFA-induced inflammatory pain, but only heightened thermal sensitivity 
following SNI-induced neuropathic pain. When administration of i.t AMP failed to produce any 
behavioral outcomes in NT5E-/- mice, it was hypothesized that adenosine generated by 
hydrolysis of AMP by any remaining nucleotidases was being converted by adenosine kinase or 
adenosine deaminase to AMP or inosine, respectively, before it was able to activate A1R. Thus, 
the ENT and adenosine kinase inhibitor, 5’-iodotubercidin (ITU), was co-administered with 
AMP [106]. Subsequently, NT5E-/- mice showed moderate increases in thermal withdrawal 
latencies compared to WT mice, whereas A1R-/- mice did not show any changes in withdrawal 
latencies. Following CFA-induced inflammatory pain, NT5E-/- mice given i.t. AMP + ITU 
showed blunted recovery of thermal withdrawal latencies compared to WT mice. Collectively, 
these data suggest that NT5E contributes to AMP hydrolysis in vivo, and that the antinociceptive 
effects are dependent both on the generation of adenosine and subsequent activation of A1R. 
[104] 
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 Further evaluation of the effect of i.t. hPAP revealed a possible link between A1R 
activation and modulation of TRPV1 activity, which could explain the observed thermal 
antihyperagesic effects following i.t. administration of hPAP. Activation of TRPV1 has been 
shown to be modulated by levels of PIP2, and there are two opposing theories regarding the 
regulation of TRPV1 by PIP2. The first suggests the presence of PIP2 in the membrane inhibits 
TRPV1 function, and cleavage of PIP2 by PLC releases TRPV1 from this inhibition [107]. 
Conversely, the second mechanism suggests that PIP2 is necessary for TRPV1 function, that 
cleavage of PIP2 leads to desensitization TRPV1, and that re-synthesis of PIP2 is necessary for 
channel recovery [108]. Later studies indicated that the apparent discrepancy regarding 
modulation of TRPV1 activity by PIP2 is dependent upon the concentration of capsaicin used. 
Strong stimuli (i.e. high capsaicin) results in activation of PLC leading to cleavage of PIP2 and 
desensitization of TRPV1, whereas with mild to moderate stimuli PIP2 exhibits an inhibitory 
effect on TRPV1 and cleavage of PIP2 relieves this inhibition [109]. In relation to i.t. hPAP-
mediated antinociception, activation of A1R is associated with activation of PLC. Thus, 
interventions (such as i.t. hPAP) that increase extracellular levels of adenosine, leading to 
increased activation of A1R, may be able to modulate thermal hyperalgesia by activating PLC 
and cleaving PIP2, thereby inhibiting TRPV1 channel activity [110].  
To further investigate the role of PAP and NT5E in modulating nociceptive circuitry, 
Zylka and colleagues generated double knockout mice that were deficient in both PAP and NT5E 
(dKO) [105]. PAP and NT5E have different pH profiles at which they are most effective. PAP is 
an acid phosphatase and thus has optimal activity at acidic pH, specifically pH 5.6, at which it 
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can hydrolyze AMP, ADP and ATP. PAP is also able to hydrolyze AMP >> ADP at neutral pH 
(pH 7.0) [111]. The optimal pH for NT5E-mediated hydrolysis of AMP is pH 7.0 [104]. Double 
knockout mice exhibited near complete loss of AMP hydrolytic activity at both pH 7.0 and pH 
5.6 in small and medium diameter neurons, revealing the PAP and NT5E are the primary 
enzymes in the DRG and spinal cord responsible for hydrolyzing AMP. Furthermore, the 
behavioral responses of dKO mice following i.t. AMP + ITU were analogous to those of A1R-/- 
mice, providing further evidence that PAP and NT5E are responsible for hydrolyzing AMP into 
adenosine, and that activation of A1R is responsible for the observed antinociceptive effects in 
inflammatory and neuropathic pain models. [105]  
Collectively, these data indicate that PAP and NT5E are located on small diameter, 
putative nociceptive neurons in the DRG, as well as in the central terminals where these sensory 
nociceptive neurons terminate in the dorsal horn of the spinal cord, placing them in prime 
location to modulate nociceptive signaling. These enzymes both hydrolyze AMP to generate 
adenosine and, thus, exert their antinociceptive effects through activation of A1R. Following 
activation of A1R, several downstream signaling pathways are activated, including inhibition of 
adenylyl cyclase and decreased production of cAMP, as well as activation of PLC leading to 
cleavage of PIP2 and possible modulation of TRPV1-mediated thermal hyperalgesia.    
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Statement of Purpose 
In the chapters that follow, the case will be made that diabetes disrupts endogenous 
activation of the A1R-mediated antinociceptive pathway. Moreover, in vivo studies will show 
that activation of this pathway can alleviate signs of mechanical allodynia in diabetic mice, 
despite the effect of diabetes on endogenous antinociceptive signaling. Importantly, these studies 
are the first to show that diabetes affects the ability of ectonucleotidases to hydrolyze AMP, thus 
disrupting endogenous production of adenosine and activation of the antinociceptive adenosine 
A1 receptor. Under physiological conditions, activation of A1R by adenosine exerts a tonic 
inhibitory effect on neurons in the dorsal horn, and disruption of this endogenous antinociceptive 
pathway leads to a loss of inhibition and a concurrent increase in excitatory glutamatergic 
signaling [112]. Interference of endogenous activation of A1R as a consequence of long-standing 
hyperglycemia and diabetes could be yet another mechanism underlying the development of 
painful diabetic neuropathy. Indeed, P1 receptor activation (A1R activation) is often considered 
to be opposite and counteractive to P2 receptor activation (P2X and P2Y receptor activation). 
Currently, there are no medications approved by the FDA that treat the underlying 
pathogenesis contributing to the development of painful diabetic neuropathy. This highlights the 
need to develop new therapeutic options for managing painful diabetic neuropathy based on the 
underlying mechanisms, rather than just symptomatic treatment. Studies contained herein will 
show that although diabetes disrupts adenosine production, this important antinociceptive 
pathway can still be targeted to significantly improve mechanical sensitivity in the setting of 
painful diabetic neuropathy. Furthermore, these studies show that central and peripheral delivery 
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of pharmacological agents which activate A1R can alleviate signs of painful diabetic neuropathy, 
mitigating the potential for systemic adverse effects that are often seen following oral or 
intravenous drug administration.    
In summary, these studies support the hypothesis that diabetes alters endogenous 
adenosine production through inhibition of enzymatic hydrolysis of AMP, and that activation of 
A1R can provide a novel target for treating painful diabetic neuropathy in humans.  
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CHAPTER 2 
Central delivery of A1R agonists reverse mechanical allodynia in a rodent model of painful 
diabetic neuropathy 
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1. Abstract 
Painful diabetic neuropathy (PDN) is one of the most common and debilitating 
complications of diabetes mellitus. The current study used a mouse model of PDN to test the 
hypothesis that the antinociceptive adenosine A1 receptor (A1R) is a potential therapeutic target 
for the treatment of PDN. Seven weeks following i.p. injection of streptozocin (STZ), diabetic 
mice displayed a significantly decreased ability of ectonucleotidases in the dorsal root ganglia to 
hydrolyze adenosine monophosphate (AMP) into adenosine, as well as a significant decrease in 
hindpaw mechanical withdrawal threshold. Intrathecal injection of the ectonucleotidase prostatic 
acid phosphatase was ineffective at alleviating mechanical allodynia; however, co-administration 
of AMP or adenosine with the adenosine kinase inhibitor, 5-iodotubercidin, transiently increased 
mechanical withdrawal thresholds in diabetic mice to nondiabetic levels. Intrathecal 
administration of the direct A1R agonist, N6-cyclopentyladenosine (CPA), reinforced that this 
behavioral outcome was the result of A1R activation. This study demonstrates that diabetes 
affects endogenous adenosine production, but that this important antinociceptive pathway can 
still be activated via central delivery of A1R agonists, resulting in an improvement in mechanical 
sensitivity in diabetic mice.  
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2. Introduction 
Diabetic neuropathy is one of the most common and debilitating symptoms of diabetes, 
and up to 30% of patients with diabetic neuropathy experience symptoms of pain that negatively 
impact their quality of life [17, 113]. Painful symptoms can include spontaneous sensations such 
as burning or tingling (paresthesias), increased sensitivity to a normally innocuous stimuli 
(allodynia), or heightened sensitivity to an already painful stimulus (hyperalgesia). Several 
mechanisms are thought to contribute to the development of painful neuropathy, including 
damage, sensitization, altered trophic support, or spontaneous activity of peripheral pain nerves; 
central sensitization of dorsal horn neurons; spinal microglial activation; alterations in 
descending pain control; and altered molecular signaling within the peripheral and central 
nervous system [5, 113-115]. Unfortunately for these patients, few treatment options exist that 
provide symptomatic relief and most are either ineffective or have intolerable side effects [27, 
115-117]. 
Pain sensation from the periphery is conveyed through thinly myelinated Aδ-fibers, and 
unmyelinated C-fibers. As discussed in Chapter 1, these fibers typically have a high threshold for 
activation, and, thus, primarily convey noxious sensations in the form of heat, cold, mechanical 
or chemical stimuli. Specific channels and receptors on these nociceptive neurons are responsible 
for converting these environmental cues into electrical signals that are processed by the central 
nervous system. Activation of certain receptors results in inhibition of pain transmission, and 
these receptors can be considered antinociceptive, such as the adenosine A1 receptor (A1R). A1R 
is a G-protein coupled receptor that is activated by adenosine, and is expressed in both the 
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peripheral and central nervous system. Activation of this receptor has been implicated in 
mitigating pain sensation in a variety of neuropathic pain conditions, primarily through inhibition 
of excitatory signals to higher processing centers [112, 118-120]. 
Extracellular adenosine is generated through two main sources: hydrolysis of 
extracellular AMP by ectonucleotidases, or though release of intracellular adenosine by 
equilibrative nucleotide transporters in the cell membrane. Two ectonucleotidases, prostatic acid 
phosphatase (PAP) and ecto-5’-nucleotidase (NT5E), have recently been identified on putative 
nociceptive neurons, and are believed to mitigate pain sensation by hydrolyzing AMP into 
adenosine and activating A1R (covered in detail in Chapter 1). However, the effect of diabetes 
on ectonucleotidase expression and function remained unknown. Here, we show that diabetes 
does indeed affect ectonucleotidase activity, primarily on small- and medium-diameter neurons 
in the DRG, which are associated with transmitting pain sensation from the periphery to the 
central nervous system.  
Current treatment options for painful diabetic neuropathy are limited primarily to 
symptomatic treatment and come with significant risk of side effects and questionable efficacy. 
None of the currently available treatment options for painful diabetic neuropathy are aimed at 
treating the pathogenesis underlying development of the disease [17]. Furthermore, very few 
studies have ever investigated the potential of A1R-mediated antinociception as a potential novel 
treatment option for painful diabetic neuropathy, and most studies evaluating this outcome 
investigated the effects on thermal and chemical nociception. As such, we sought to determine if 
A1R activation could modulate pain sensation in diabetic mice that display signs of mechanical 
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allodynia, a symptom often associated with painful diabetic neuropathy.  Indeed, we were able to 
show that central activation of A1R was able to reverse mechanical allodynia in diabetic mice 
.  
3. Experimental Procedures 
Animals 
All experiments were approved by the University of Kansas Medical Center Institutional 
Animal Care and Use Committee. Inbred male A/J mice were obtained from Jackson 
Laboratories at 7 weeks of age, and were induced with diabetes at 8 weeks of age. All mice were 
housed in the Laboratory Animal Resources building, had ad libitum access food and water, and 
maintained on a 12 hour light/dark cycle. All mice were euthanized at 16 weeks of age.  
Streptozocin induction of diabetes 
Male A/J mice were injected with Streptozocin (STZ; Sigma, St. Louis, MO) at 8 weeks 
of age to induce type 1 diabetes. Mice were fasted for 3 hours before and after injections, for a 
total fasting time of 6 hours. Injections were spread over 2 days, with the first dose (day 1) at 85 
mg/kg and the second dose (day 2) at 65 mg/kg. Solutions were made fresh immediately prior to 
injection and STZ was dissolved in ice cold 10 mM sodium citrate buffer with 0.9% NaCl at pH 
4.5, and then filter sterilized. Control, nondiabetic mice were injected with sodium citrate buffer 
only. Animals that did not reach hyperglycemia (blood glucose >230 mg/dL) within one week 
following initial injections were re-injected with either 85 mg/kg STZ (blood glucose <180 
mg/dL) or 65 mg/kg STZ (blood glucose 181-230 mg/dL). Mice that failed to reach 
hyperglycemia were excluded from the study. 
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Blood glucose measurements  
Weight and blood glucose measurements (glucose diagnostic reagents; Sigma) were 
collected one week after initial injection and every week thereafter. Mice were fasted for 3 hours 
prior to collection of blood collection from the tail. Mice were considered diabetic when blood 
glucose levels were >230 mg/dL.  
Behavioral analysis 
Prior to behavioral testing, mice were acclimated to the behavior facility and equipment 
for a minimum of 2 days. On test days, mice were placed in the behavior facility and allowed to 
acclimate to the environment for at least 30 minutes. Mice were then acclimated on the behavior 
apparatus for 20 to 30 minutes prior to initiating testing. Mice were placed in individual clear 
plastic cages on top of a wire mesh grid that allowed access to their hind paws for the duration of 
the analysis. Mechanical withdrawal thresholds using von Frey monofilaments were measured 
weekly to track progression of neuropathy phenotype using the up-down method to determine 
fifty percent withdrawal thresholds [121]. Tests for mechanical sensitivity following intrathecal 
(i.t.) injections were performed at 30 min, 1.5 hours, 3 hours and 5 hours following injection; 
mechanical sensitivity following injection of i.t. purified human PAP (hPAP) was evaluated at 
24, 48, 72 and 120 hours post-injection.  
Drugs and Drug Administration 
Adenosine (Ado), AMP and CPA (direct A1R agonist) were purchased from Sigma; 
hPAP was graciously provided by Dr. Mark Zylka (University of North Carolina). 
5’iodotubercidin (ITU; adenosine kinase inhibitor) was purchased from Enzo Life Sciences. 
AMP, Ado, and CPA were dissolved in 0.9% saline at pH 7.4. AMP was delivered at a 
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concentration of 200 nmol/10 µl [104]; Ado and CPA were delivered at 10 nmol/10 µl  [122, 
123]; hPAP was dissolved in saline and delivered at a dose of 250 mU/10 µL [100]. ITU was co-
administered with Ado or AMP at a concentration of 5 nmol/10 µL [124]. Intrathecal injections 
(hPAP, AMP + ITU, Ado + ITU, CPA) were performed using a 28 gauge, 8 mm insulin syringe 
(BD Biosciences, San Jose, CA) using the direct lumbar puncture method between L5-L6 [125]. 
Tissue Preparation 
Mice were overdosed with inhaled isoflurane, injected with 150 µl of heparin (BD 
Biosciences) into the ventricle, and then transcardially perfused with 4% paraformaldehyde (in 1 
x PBS, pH 7.4). Lumbar spinal cord and dorsal root ganglia (DRG, L4-6) were dissected, post-
fixed in 4% paraformaldehyde for 1 hour, and cryo-protected overnight in 30% sucrose (w/v in 1 
x PBS). Tissues were frozen in OTC and stored at -20°C until sectioning. Spinal cord tissue was 
serially sectioned at 10 µm and DRG were sectioned at 8 µm; tissues were mounted on 
Suprafrost slides (Fisher Scientific, Chicago, IL) and stored at -20°C until used.  
Immunohistochemistry 
Slides were brought to room temperature in a humidity chamber, outlined with PAP Pen 
(Research Products International, Mt. Prospect, IL) to create a hydrophobic barrier, and blocked 
for one hour at room temperature in a pre-incubation solution (PIS) consisting of Superblock 
(Thermo Scientific, Rockford, IL), 1.5 % normal goat serum, 0.5% porcine gelatin and 0.5% 
Triton X-100. Primary antibodies were diluted in PIS and incubated overnight at 4°C. Slides 
were washed twice in 1 x PBST, and then incubated with secondary antibody for 1 hour at 4°C in 
1 x PBST and Superblock in a 1:1 ratio. Slides were washed twice in 1 x PBS, coverslipped and 
imaged using fluorescence microscopy. Primary antibodies included: chicken anti-PAP (1:4,000; 
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Aves Labs, Tigard, OR), isolectin IB4 Alexa Fluor 488 conjugate (1:50; Invitrogen, Carlsbad, 
CA), and rabbit-anti-TRPV1 (1:1000; Calbiochem). Secondary antibodies included: Donkey 
anti-chicken-555 (1:2000; Jackson) and donkey anti-rabbit-647 (1:2000; Invitrogen). The overall 
percent positive neurons in the DRG was determined by counting the number of PAP-positive 
neurons and the number of neurons overall in both nondiabetic and diabetic mice. Spinal cord 
slices were evaluated by placing regions around the medial and lateral one third of PAP-positive 
bands in the dorsal horn of the spinal cord in both nondiabetic and diabetic mice. Images were 
analyzed using NIS Elements software (Nikon Corporation).  
Enzyme Histochemistry  
Ectonucleotidase activity (PAP and NT5E) was quantified using enzyme histochemistry. 
Sections of spinal cord or DRG were incubated in trisma-maleate (Sigma) buffer with 8% 
sucrose (w/v; TMBS) at pH 7.4 or pH 5.6 for 30 minutes. Tissues were then incubated in TMBS 
solution containing 2.4 mM lead nitrate and either 3 mM AMP (DRG, pH 7.4) or 0.3 mM AMP 
(DRG, pH 5.6; spinal cord pH 7.4 and pH 5.6) for 2-3 hours. Tissues were developed in 0.5% 
ammonium sulfide solution, rinsed three times in TMBS, coverslipped and imaged on a light 
microscope. Positive neurons were identified by the presence of a dark brown lead phosphate 
precipitate. DRG soma areas were calculated using NIH Image J software by tracing the border 
of all positive and negative neurons. At pH 7.4, sections from 7 nondiabetic and 7 diabetic mice 
were counted, and at pH 5.6 sections from 9 nondiabetic and 8 diabetic mice were counted. A 
minimum of 500 neurons per animal were evaluated. Hydrolysis of AMP in the spinal cord was 
analyzed using NIS Elements software (Nikon Corporation) by placing regions of interest around 
the medial and lateral 1/3 of each band of precipitate in the dorsal horn. At pH 7.4, sections from 
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7 nondiabetic and 7 diabetic mice were, and at pH 5.6, sections from 5 nondiabetic and 7 diabetic 
mice were counted. A minimum of 5 dorsal horns per animal were evaluated.  
Statistical analysis 
Results were analyzed using the SPSS Statistics 20 software (IBM). Student’s t-tests and 
two-way repeated measures analysis of variance (2-way RM-ANOVA) with Fisher’s least 
significant difference (LSD) post-hoc analyses were performed, as denoted in the manuscript. A 
p-value less than 0.05 was considered significant. All data are presented as mean ± S.E.M. 
 
4. Results & Figures 
Diabetic A/J inbred mice develop mechanical allodynia.  
 Fasting blood glucose and weight measurements were taken weekly following STZ 
injection. Mice that received STZ had an average fasting blood glucose level of 432.8 +/- 18.7 
mg/dL as early as one week post-STZ injection,  whereas control mice had an average fasting 
blood glucose level of 101.7 +/- 1.9 mg/dL (Fig. 5A). Simultaneously, diabetic mice failed to 
gain weight compared to their nondiabetic counterparts (Fig. 5B). All mice underwent weekly 
behavioral testing to quantify changes in hind paw mechanical sensitivity. Beginning 3 weeks 
post- STZ injections, withdrawal threshold was significantly decreased in diabetic mice 
compared to nondiabetic mice (Fig. 5C). Withdrawal thresholds in diabetic mice reached their 
lowest levels at four weeks post-injection, and remained consistently decreased compared to 
nondiabetic counterparts for the duration of the study.  
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Figure 5. Diabetic mice develop hyperglycemia and mechanical allodynia. A) Blood glucose 
measurements of diabetic (DB) mice were significantly elevated at all time points beginning 1 
week post-STZ injection (p < 0.0001 vs. nondiabetic [ND] at all time points; 2-way RM-
ANOVA with LSD post-hoc analysis).  B) Diabetic mice failed to gain weight, unlike their ND 
counterparts (p < 0.0001 vs. ND at all time points; 2-way RM-ANOVA with LSD post-hoc 
analysis).  C) Diabetic mice displayed a significantly decreased mechanical withdrawal threshold 
beginning 3 weeks post-STZ injection that persisted throughout the duration of the study (** p < 
0.0001 vs. ND, 2-way RM-ANOVA with LSD post-hoc analysis). n = 28 – 33 mice per group. 
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Diabetes alters the ability of ectonucleotidases to hydrolyze AMP in the DRG 
Immunohistochemistry was used to confirm protein expression of PAP and NT5E on 
nonpeptidergic neurons in the DRG and spinal cord. PAP and NT5E expression overlapped 
extensively with the nonpeptidergic neuronal marker isolectin B4 (IB4) in both the DRG (Fig. 
6A-F) and spinal cord (Fig. 7A-F). There was minimal to no overlap between PAP or NT5E with 
TRPV1, which is primarily expressed on peptidergic neurons in the DRG (Fig. 6G-L) or the 
spinal cord (Fig. 7G-L). These results are in line with previous reports of PAP and NT5E 
expression in these tissues [100, 103, 104]. PAP expression was evaluated in nondiabetic and 
diabetic mice to determine the effect of diabetes on enzyme expression. No change in the overall 
percentage of positive neurons that express PAP was evident in the DRG (Fig. 8A). In the spinal 
cord, central termination patterns of nociceptors are arranged such that axons from the distal 
limbs terminate in the medial portion of the dorsal horn and axons from more proximal tissues 
terminate in the lateral portion of the dorsal horn [126]. There was no change in overall 
expression of PAP protein between nondiabetic and diabetic mice in the medial portion of spinal 
cord (Fig. 8B).  
 
 
  
57 
 
 
 
 
 
 
 
 
Figure 6. PAP and NT5E are expressed in lumbar DRG neurons. PAP (A, G) and NT5E (D, 
J) are expressed primarily on small-diameter neurons in the DRG, which also express the non-
peptidergic neuronal marker, IB4 (B, E). Merged images (C, F) show extensive overlap between 
the two markers. TRPV1 (H, K) is primarily expressed on peptidergic neurons in the DRG. 
Merged images (I, L) between TRPV1 and PAP or NT5E, show minimal overlap between the 
two markers. Arrowheads point to positive neurons that overlap in merged images. Arrows point 
to the same neuron throughout the series of images.  
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Figure 7. PAP and NT5E are expressed in the dorsal horn of the lumbar spinal cord. PAP 
(A, G) and NT5E (D, J) are primarily expressed in the dorsal horn of lumbar spinal cord sections. 
IB4 (B, E) is used as a marker of nonpeptidergic nerve terminals in the spinal cord, which 
terminate in lamina II of the dorsal horn. Merged images (C, F) show extensive overlap between 
IB4 and PAP or NT5E. TRPV1 (H, K) is primarily expressed on peptidergic neurons, which 
terminate in lamina I of the dorsal horn. Merged images (I, L) between TRPV1 and PAP or 
NT5E, show minimal overlap between the two markers.  
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Figure 8. PAP expression is not affected by diabetes in either the DRG or spinal cord. A) 
The overall percentage of neurons expressing PAP was not significantly affected by diabetes 
when comparing diabetic (DB) to nondiabetic (ND) mice (p > 0.05 vs. ND, t-test); n = 5 – 8 
mice per group. B) Expression of PAP in the dorsal horn of the spinal cord of DB mice was also 
not altered by diabetes (p > 0.05 vs. ND; t-test); n = 6 – 8 mice per group. 
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Extracellular hydrolysis of AMP is predominantly mediated by PAP and NT5E in the 
dorsal spinal cord and DRG [100, 104, 105]. NT5E is primarily active near physiological pH 
(7.0), whereas PAP is the primary enzyme active at acidic pH (5.6) [100, 104]. AMP 
histochemistry was performed on DRG and spinal cord tissues at pH 7.4 and 5.6 to evaluate the 
ability of NT5E and PAP, respectively, to degrade AMP in both diabetic and nondiabetic mice. 
Examples of AMP hydrolysis in the DRG are shown in Figure 9A. In the DRG of diabetic A/J 
mice, there was a small but statistically significant decrease in the overall percentage of neurons 
capable of hydrolyzing AMP at pH 7.4 (Fig. 9B), specifically in neurons with small soma areas 
(<300 µm2; Fig. 2C), which correspond to neurons within the small-diameter range. At acidic 
pH, there was no change in the overall percentage of positive neurons in the DRG (Fig. 9B); 
however there was a significant decrease in the percentage of positive neurons in neurons with 
soma areas that correspond to the small- (< 300 µm2) and medium-diameter (301-600 µm2) range 
(Fig. 9D). Examples of AMP hydrolysis at pH 7.4 and 5.6 in the dorsal horn of nondiabetic and 
diabetic mice are shown in Figure 10A. Assessment of enzyme activity in the medial portion of 
the dorsal horn revealed no significant differences in staining density or patterns between 
nondiabetic and diabetic mice at physiological or acidic pH (Fig. 10B) [97]. 
Modulation of nociception by AMP hydrolysis in diabetic mice 
Previous studies indicate that a single dose of i.t. hPAP provided long lasting (>3 days) 
antinociceptive effects in mice that had either inflammatory or neuropathic pain [100, 110, 111]. 
To determine if hPAP would have the same efficacy in painful diabetic neuropathy, a single 
injection of i.t. hPAP (250 mU/10 µl) was administered to diabetic and nondiabetic mice. 
Diabetic mice treated with i.t. hPAP had a significant reversal of their mechanical sensitivity 
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Figure 9. AMP hydrolysis is decreased in the DRG of diabetic mice. A) Representative 
images of AMP histochemistry performed in DRG sections from nondiabetic and diabetic mice 
at pH 7.4 and 5.6. Arrowheads indicate positive neurons; asterisks indicate negative neurons. B) 
The overall percentage of neurons displaying evidence of hydrolyzed AMP at pH 7.4 was 
significantly decreased in diabetic (DB) mice, compared to nondiabetic (ND) mice (*p <0.05 vs. 
ND, t-test). There was no significant difference in the overall percentage of neurons capable of 
hydrolyzing AMP at pH 5.6 (*p > 0.05 vs. ND, t-test). C) The percentage of positive neurons 
was significantly decreased only within small-diameter (< 300 µm2) neurons at pH 7.4 (*p <0.05 
vs. ND, 2-way RM-ANOVA with LSD post-hoc analysis). D) At pH 5.6, the percentage of 
positive neurons was significantly decreased within both the small- (< 300 µm2) and medium-
diameter (301-600 µm2) neurons (*p <0.05 vs. ND, 2-way RM-ANOVA with LSD post-hoc 
analysis). n = 7 mice per group.  
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Figure 10. Diabetes does not affect AMP hydrolysis in the dorsal horn of the lumbar spinal 
cord. A) Representative images of AMP histochemistry in dorsal horn sections from nondiabetic 
(ND) and diabetic (DB) mice at pH 7.4 and pH 5.6. B) No significant difference in AMP 
hydrolysis was observed between ND and DB mice at pH 7.4 or at pH 5.6 in the medial portion 
of the dorsal horn (*p > 0.05 vs. ND, t-test). n = 5 -7 mice per group.  
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at 24 hours post-injection compared to baseline values (p = 0.02, Fig. 11A); however, this this 
was not significantly different than diabetic vehicle treated mice at 24 hours. There were no 
significant differences in mechanical withdrawal thresholds between nondiabetic hPAP treated 
and nondiabetic vehicle treated mice at any time point. At 24 hours post-injection there was no 
significant difference between nondiabetic and diabetic hPAP treated mice. 
Subsequently, i.t. AMP (200 nmol/10 µl) was administered to determine whether the 
endogenous hydrolytic activity of these enzymes was sufficient to generate adenosine and 
activate antinociceptive pathways. When given alone, neither AMP (Fig. 12A; or adenosine, Fig. 
12B) nor ITU (Fig. 12C) produced any changes in mechanical sensitivity in diabetic. However, 
when AMP was co-administered with ITU (i.t. AMP + ITU) diabetic mice showed a significant, 
but transient, reversal of their mechanical sensitivity at 30 min (p = 0.01) compared to pre-
treatment withdrawal thresholds (Figs. 11B). The withdrawal threshold of AMP + ITU treated 
diabetic mice was also significantly different than diabetic vehicle treated mice at 30 min (p = 
0.002) following administration. There were no significant differences between nondiabetic 
AMP + ITU treated mice and nondiabetic vehicle treated mice.  
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Figure 11. Supplementation of i.t. hPAP and AMP + ITU transiently alleviates mechanical 
sensitivity in diabetic mice. A) Diabetic (DB) mice administered i.t. hPAP (250 mU/10 µl) 
showed a significant improvement in mechanical withdrawal thresholds compared to baseline 
levels after 24 hours (# p < 0.05 vs. DB hPAP, 2-way RM-ANOVA with LSD post-hoc 
analysis); however this was not significantly different from diabetic vehicle treated mice at 24 
hours (p > 0.05 vs. DB Veh, 2-way RM-ANOVA with LSD post-hoc analysis). n = 9 – 10 mice 
per group. B) Diabetic mice administered i.t. AMP + ITU (AMP, 200 nmol/10 µl; ITU, 5 
nmol/10 µl) showed a transient, but significant, reversal in their mechanical sensitivity at 30 min 
following injection compared to baseline (## p = 0.01 vs. DB AMP + ITU, 2-way RM-ANOVA 
with LSD post-hoc analysis) and to DB vehicle treated mice (**p < 0.01 vs. DB Veh, 2-way 
RM-ANOVA with LSD post-hoc analysis), which returned to pre-injection withdrawal 
thresholds after 1.5 hours. n = 9 – 10 mice per group.  
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Figure 12. Neither i.t. AMP, i.t. Ado nor i.t. ITU alleviate mechanical allodynia when given 
individually. A) Diabetic (DB) mice administered i.t AMP (200 nmol/10 µl) alone did not show 
any significant improvement in mechanical withdrawal thresholds compared to baseline (p > 
0.05 vs. DB AMP, 2-way RM-ANOVA with LSD post-hoc analysis), or DB-vehicle treated mice 
(p > 0.05 vs. DB Veh, 2-way RM-ANOVA with LSD post-hoc analysis). n = 5 mice per group. 
B) DB mice that received only i.t. Ado (10 nmol/10 µl) showed no significant reversal in 
mechanical allodynia compared to baseline (p > 0.05 vs. DB Ado, 2-way RM-ANOVA with 
LSD post-hoc analysis), or DB-vehicle treated mice (p > 0.05 vs. DB Veh, 2-way RM-ANOVA 
with LSD post-hoc analysis). n = 5 mice per group. C) DB mice given i.t. ITU (5 nmol/10 µl) 
alone did not show any significant improvements in mechanical withdrawal thresholds compared 
to baseline (p > 0.05 vs. DB ITU, 2-way RM-ANOVA with LSD post-hoc analysis), or DB-
vehicle treated mice (p > 0.05 vs. DB Veh, 2-way RM-ANOVA with LSD post-hoc analysis). n 
= 4 mice per group.  
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Direct activation of spinal A1Rs reverses mechanical allodynia. 
 Finally, mechanical sensitivity was assessed following direct activation of A1R by i.t. 
administration of adenosine (with ITU, Ado + ITU, 10 nmol/10 µl) or CPA (10 nmol/10 µl), a 
specific A1R agonist and stable adenosine analog. Diabetic mice that received Ado + ITU 
displayed a significant increase in mechanical withdrawal threshold for at least 5 hours compared 
to baseline (p < 0.01), as well as compared to diabetic vehicle treated mice (p < 0.05); at 5 hours 
post-i.t. Ado +ITU, the mechanical withdrawal thresholds of diabetic mice had not yet return to 
pre-treatment levels (Fig. 13A). There were no significant differences between nondiabetic Ado 
+ ITU treated and vehicle treated mice. Diabetic mice that received i.t. CPA also displayed a 
significant increase in mechanical withdrawal threshold compared to baseline and compared 
diabetic vehicle treated mice, lasting through the 1.5h time point (p < 0.01; Fig. 13B).  
 
5. Discussion 
Painful diabetic neuropathy affects a significant proportion of individuals with diabetic 
neuropathy, and although many mechanisms have been identified as potential underlying causes 
of diabetic neuropathy, few of these mechanisms have resulted in the development of a 
successful therapeutic treatment options to alleviate pain associated with diabetic neuropathy. 
Rodent models have been key to understanding the pathogenesis of both diabetic neuropathy and 
painful diabetic neuropathy. Here, we show that inbred male A/J mice develop a robust 
mechanical allodynia following induction of type 1 diabetes, providing a reliable model for 
investigating the development of painful diabetic neuropathy as well as potential therapeutic  
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Figure 13. Central delivery of Ado + ITU or CPA provides long-lasting anti-allodynic 
effects in diabetic mice. A) Diabetic (DB) mice that received i.t. Ado + ITU (Ado, 10 nmol/10 
µl; ITU, 5 nmol/10 µl) showed a significant reversal of mechanical sensitivity compared to 
baseline (## p < 0.01 vs. DB Ado + ITU, 2-way RM-ANOVA with LSD post-hoc analysis) and 
diabetic vehicle treated mice (* p < 0.05 vs. DB Veh, 2-way RM-ANOVA with LSD post-hoc 
analysis) that lasted over 5 hours, at which time withdrawal thresholds had not yet returned to 
baseline levels. Withdrawal thresholds of DB mice that received i.t. Ado + ITU were not 
significantly different from ND Ado + ITU treated mice at any time point. n = 5 – 8 mice per 
group. B) Intrathecal CPA (10 nmol/10 µl) also significantly reversed mechanical withdrawal 
thresholds in diabetic mice compared to baseline (## p < 0.01 vs. DB CPA, 2-way RM-ANOVA 
with LSD post-hoc analysis) and diabetic vehicle treated mice (** p < 0.01 vs. DB Veh, 2-way 
RM-ANOVA with LSD post-hoc analysis) for up to 3 hours. Additionally, ND mice that 
received i.t. CPA had significantly elevated withdrawal thresholds compared to ND vehicle 
treated mice at 1.5 hours following treatment (^ p < 0.05 vs. ND Veh; 2-way ANOVA with LSD 
post-hoc analysis). n = 5 – 9 mice per group.  
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interventions. Identification of the involvement of ectonucleotidases in mitigating pain 
transmission spurred renewed interest in the effect of diabetes on these enzymes and the 
downstream activation of important antinociceptive signaling pathways.   
Nucleotides, such as ATP, can be released into the extracellular space from vesicles at 
nerve synapses, and also following tissue injury from damaged and dying cells [67]. These 
nucleotides can then go on to activate P2X and P2Y receptors (see Chapter 1) expressed 
throughout the nervous system, resulting in pain sensation and nociceptive neurotransmission 
[67, 68, 127]. Ectonucleotidases function to terminate this nociceptive signaling by hydrolyzing 
pro-nociceptive nucleotides into the antinociceptive small molecule adenosine. Recently, Zylka 
and colleagues demonstrated the important role that PAP and NT5E play in modulating 
mechanical allodynia and thermal hyperalgesia in rodent models of inflammatory and 
neuropathic pain [100, 104].  
 
Diabetes affects AMP hydrolysis in the central nervous system 
In the DRG, PAP and NT5E have been shown to co-localize extensively with markers 
that are used to identify nonpeptidergic, putative nociceptive neurons such as P2X3, IB4 and 
Mrgprd [100, 103, 104]. Additionally, both enzymes are expressed in lamina II of the spinal cord 
where the central projections of these non-peptidergic fibers terminate, placing them in prime 
location to modulate nociceptive signaling [100, 103, 104]. Immunohistochemistry revealed a 
similar general pattern of expression for both PAP and NT5E in the DRG and spinal cord of A/J 
mice. Immunohistochemical analysis of PAP did not reveal any changes in overall expression of 
PAP between diabetic and nondiabetic mice in the DRG or spinal cord.  
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Because there was no change in enzyme expression levels, we hypothesized that diabetes 
may affect enzyme activity, rather than overt expression levels. Our laboratory has previously 
shown that TMPase activity is decreased in the dorsal horn of diabetic mice, and TMPase was 
recently identified as the membrane bound form of PAP [97, 100]. NT5E is primarily active near 
physiological pH (pH 7.0), while PAP is mainly active at acidic pH (pH 5.6); however, both 
enzymes contribute to AMP hydrolysis in vivo [100, 104]. In the current study, the preferred pH 
of these enzymes was exploited to determine the relative contribution of each enzyme towards 
AMP hydrolysis. The results revealed decreased hydrolytic activity of AMP following 8 weeks 
of diabetes at both pH 7.4 and pH 5.6, indicating that the enzymatic activity of both 
ectonucleotidases was affected by diabetes. At this time, diabetic mice displayed significant 
mechanical allodynia, suggesting that reduced adenosine production may contribute to their 
altered sensory phenotype. To our knowledge these are the first studies to show that diabetes has 
an effect on the hydrolytic capacity of ectonucleotidases in the central nervous system, despite 
not interfering with protein expression levels.  
 
Endogenous adenosine production can transiently reverse mechanical allodynia 
Previous studies have shown that a single i.t. injection of hPAP can alleviate mechanical 
allodynia and thermal hyperalgesia in rodent models of inflammatory and neuropathic pain for 
up to three days, and these results were dependent on A1R activation [100, 110]. Injection of i.t. 
hPAP was able to improve withdrawal thresholds in diabetic mice compared to baseline after 24 
hours, but this effect did not last past 48 hours. This lack of efficacy could be due to chronic 
hyperglycemia interfering with intrinsic enzyme activity, as was seen using AMP histochemistry, 
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thus preventing maximal activation of A1R. Alternatively, it is possible that the peak 
antinociceptive effect of i.t. hPAP occurred prior to the 24 hour time point in our model of 
painful diabetic neuropathy, thereby preventing our ability to observe a significant 
antinociceptive effect following administration of i.t hPAP. Lack of sufficient substrate (AMP) 
for enzyme activation was ruled out by the observation of significantly increased mechanical 
withdrawal threshold following i.t. AMP + ITU administration in diabetic mice. 
Adenosine is rapidly converted in vivo to inosine via adenosine deaminase (ADA) or 
phosphorylated into AMP by adenosine kinase (AK) [52, 94, 128]. Previous studies have 
suggested the use of inhibitors for ADA or AK as potential therapeutic treatment options to 
effectively increase the concentration of adenosine present in the extracellular space [106, 129]. 
The AK inhibitor, ITU, was co-administered with AMP to promote activation of A1R. Diabetic 
mice treated with AMP + ITU displayed a transient reversal of mechanical sensitivity at 30 min 
following injection, but this returned to pre-treatment withdrawal thresholds within 1.5 hours. 
This suggests that despite decreased enzymatic activity as a consequence of diabetes, AMP 
hydrolysis was sufficient to generate enough adenosine to activate A1R and alter mechanical 
sensitivity.  
 
Central activation of A1R modulates nociception in diabetic mice 
Several studies have shown that the antinociceptive properties of adenosine are driven by 
activation of A1R through the use of selective agonists and antagonists [110, 112, 123, 130-135]. 
Tian et al. report that A1R is under tonic activation by adenosine, which may contribute to 
setting a “physiological nociceptive threshold” [112]. Disturbances in this balance, as suggested 
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here by decreased enzymatic activity leading to decreased adenosine production, could shift the 
threshold from a normal pain-free setting to a pro-nociceptive condition that could influence pain 
states under chronic disease conditions. Additionally, Guieu et al. report that patients with 
chronic neuropathic pain have lower circulating levels of adenosine in their blood and 
cerebrospinal fluid, and this loss of tonic activation of antinociceptive pathways could contribute 
to increased pain sensation in chronic disease settings [136].  
As discussed in Chapter 1, A1R expression has been extensively studied and 
characterized in the DRG and spinal cord. PAP and NT5E are expressed on a subset of A1R-
expressing neurons, suggesting these enzymes may act locally to modulate nociceptive tone 
through hydrolysis of AMP and subsequent activation of localized A1Rs. In this study, i.t. 
delivery of Ado + ITU was able to significantly reverse mechanical withdrawal thresholds in 
diabetic mice for over five hours, suggesting that central activation of A1R may provide an 
endogenous mechanism for alleviating signs of painful diabetic neuropathy. Because adenosine 
can act at any of the four adenosine receptors, the stable adenosine analog and direct activator of 
A1R, CPA, was used to confirm that the behavioral outcomes observed in response to i.t. Ado + 
ITU were in fact due to activation of A1R. This study shows that activation of A1R by CPA 
resulted in a reversal in mechanical sensitivity that lasted several hours, similar to adenosine, 
when compared to indirect activation through hydrolysis of AMP via ectonucleotidases, which 
was only effective for 30 min following injection. Collectively, these data show that both 
adenosine and CPA were both capable of alleviating mechanical sensitivity, and these results are 
likely mediated through activation of A1R. 
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Conclusions 
In summary, this study utilized a rodent model of painful diabetic neuropathy to evaluate 
the effect of diabetes on endogenous antinociceptive signaling pathways. For the first time, we 
show that diabetes significantly decreases the ability of ectonucleotidases, such as PAP and 
NT5E, on small-diameter, putative nociceptive neurons to hydrolyze AMP leading to decreased 
production of adenosine. Decreased adenosine production in turn leads to decreased activation of 
A1R, loss of inhibition of excitatory interneurons and subsequent increased excitatory signaling. 
Collectively, loss of tonic activation of A1R leading to increased excitatory signaling could be 
one mechanism contributing to the development of painful diabetic neuropathy.   
 Finally, using a series of in vivo experiments we were able to show that central activation 
of A1R can successfully alleviate mechanical allodynia associated with painful diabetic 
neuropathy. Individually, neither AMP, adenosine nor ITU were capable of improving 
mechanical withdrawal thresholds. Additionally, indirect activation of A1R following hydrolysis 
of AMP by either i.t. hPAP or remaining endogenous AMPase activity were only minimally 
effective at alleviating signs of painful diabetic neuropathy.  Conversely, direct activation of 
A1R by either adenosine or CPA was extremely effective at reversing mechanical allodynia for 
several hours. Our results confirm that adenosine-mediated antinociception via A1R activation 
can successfully improve mechanical allodynia in a rodent model of painful diabetic neuropathy.  
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CHAPTER 3 
Downstream signaling involved in A1R-mediated antinociception 
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1. Abstract 
Activation of A1R is attributed with antinociceptive benefits. Upon activation, the G-
protein associated with this GPCR dissociates from the receptor and can go on to activate a 
variety of second messenger systems, resulting in signal amplification. Pathways downstream of 
A1R activation include inhibition of adenylyl cyclase and decreased cAMP production, with 
subsequent inhibition of PKA activation; Akt activation, presumably through activation of PI3K; 
inhibition of calcium channel signaling; and modulation of TRPV1 activity. The purpose of this 
study was to identify pathways are involved in A1R mediated antinociception. Following i.t. 
administration of Ado + ITU, there was overall decrease in cAMP levels at 30 min compared to 
baseline in the spinal cord, and no activation of PKA was detected. Surprisingly, Akt was 
robustly activated following i.t. administration of the selective A1R agonist, CPA. Although no 
changes in calcium channel expression were detected in the spinal cord or DRG of diabetic mice 
compared to nondiabetic mice, primary DRG cultures from diabetic mice showed an increased 
area under the curve (AUC) in response to the TRPV1 agonist, capsaicin. Overnight incubation 
with adenosine was able to return this increased AUC to control levels, as well as decrease the 
overall percentage of neurons that responded the stimulation with capsaicin. Collectively, these 
data suggest that cAMP- and Akt-mediated downstream signaling are involved in the 
antinociceptive actions of A1R, and that activation of A1R can modulate calcium homeostasis, in 
part, through modulation of TRPV1 activity.  
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2. Introduction 
Adenosine signaling in the central nervous system has been implicated in a variety of 
roles including normal physiological processes as well as in pathological conditions, and has 
been shown to have neuroprotective benefits when activated under pathological conditions [52, 
78]. The outcomes of adenosine-mediated signaling are dependent upon the receptor subtype 
activated, with a majority of work focused on the downstream signaling effects of A1R and 
A2AR. These two receptors essentially work in opposition to one another, with activation of 
A2AR associated with decreased GABAergic signaling and hence increased excitatory signaling, 
whereas activation of A1R is associated with decreased excitatory signaling through inhibition of 
pro-nociceptive neurotransmitter release. Thus, activation of A1R is attributed with 
antinociceptive outcomes.  
Several second messenger pathways have been associated with adenosine receptor 
activation which can regulate a variety of intracellular processes. All adenosine receptors are 
GPCRs and couple primarily to either Gαs or Gαi regulatory α-subunits of the associated 
heterotrimeric g-protein. Classically, activation of adenosine receptors is linked to modulation of 
adenylyl cyclase activity and cAMP production [137, 138]. A2AR is coupled to Gαs leading to 
activation of adenylyl cyclase and increased production of cAMP, while A1R is coupled to Gαi 
which inhibits adenylyl cyclase resulting in decreased production of cAMP. Protein kinase A 
(PKA) activity can be modulated by cAMP levels, and activation of PKA can lead to vesicular 
release at nerve synapses. For example, cAMP-dependent PKA-mediated signaling in neurons 
has been linked to neurotransmitter release [139], synaptic plasticity and memory formation 
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[140], and long-term potentiation [141]. Additionally, PKA can activate cAMP response element 
binding protein (CREB) which can regulate nuclear gene transcription.  
Another important second messenger pathway associated with adenosine receptor 
activation is that of phosphatidylinositol 3-kinase (PI3K) and protein kinase B (PKB, also known 
as Akt). Activation of the PI3K/Akt signaling pathway downstream of adenosine receptors has 
been implicated in a variety of physiological processes, including protection from ischemia-
reperfusion-induced renal injury (A1R-mediated) [142], regulation of vascular smooth muscle 
tone in the heart (A2AR-mediated) [143], and inhibition of IL-12 production, which can modulate 
activation of the innate immune system (A3R-mediated) [144]. Furthermore, in the nervous 
system, activation of PI3K/Akt signaling downstream of A1R activation has been shown to have 
neuroprotective benefits in acute (stroke) and chronic (Alzheimer’s disease) neurodegenerative 
diseases [80], in addition to regulating neuronal excitability through modulation of 
neurotransmitter release.  
Finally, activation of adenosine receptors has been shown to modulate calcium signaling, 
both intracellularly and extracellularly. Activation of phospholipase C (PLC) downstream of 
A1R leads to cleavage of PIP2 and generation of IP3 and DAG. Binding of IP3 to its receptor can 
mobilize intracellular calcium stores ([Ca2+]i) from the endoplasmic reticulum, which, together 
with DAG, can activate protein kinase C (PKC) resulting in further propagation of signaling 
cascades. Additionally, PIP2 has been shown to modulate the calcium-permeable TRPV1 
channel and can be either excitatory or inhibitory depending upon the strength of stimulus used 
for channel activation (see Chapter 1) [109]. In the context of A1R activation, it has been 
proposed that downstream activation of PLC and subsequent cleavage of PIP2 results in 
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inhibition of TRPV1 and, therefore, improvement in thermal withdrawal latencies in 
inflammatory and neuropathic pain models [110].  
In Chapter 2 we described how altered adenosine production may contribute to the 
development of painful diabetic neuropathy. Moreover, we showed that activation of the A1R-
mediated antinociceptive pathway was able to alleviate signs of mechanical allodynia in a rodent 
model of painful diabetic neuropathy. In the current study, we sought to determine where 
possible areas of dysregulation are evident, and which downstream pathways were activated 
following activation of A1R that might be contributing to the observed antiallodynic effects.  
 
3. Experimental Procedures 
Animals 
All experiments were approved by the University of Kansas Medical Center Institutional 
Animal Care and Use Committee. Inbred male A/J mice were obtained from Jackson 
Laboratories at 7 weeks of age, and were induced with diabetes at 8 weeks of age (reference 
Chapter 2). All mice were housed in the Laboratory Animal Resources building, had ad libitum 
access food and water, and maintained on a 12 hour light/dark cycle. All mice were sacrificed at 
16 weeks of age.  
Western Blot Analysis 
At sacrifice, spinal cord and DRG were flash frozen in liquid nitrogen and stored at -
80°C until processing. Tissues were sonicated in cell extraction buffer (Invitrogen, Carlsbad, 
CA) containing 55.5 µl/mL protease inhibitor cocktail (Sigma, St. Louis, MO), 200 mM Na3VO4 
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and 200 mM NaF for 60 min on ice with gentle vortexing every 10 min for protein extraction. 
Following centrifugation at 7000 rpm for 10 min at 4°C, the protein concentration of the 
supernatant was determined using the Bradford assay (Bio-Rad, Hercules, CA). Samples were 
boiled with lane marker reducing sample buffer (Thermo Scientific, Waltham, MA) and stored at 
-20°C until use. Equal amounts of protein were loaded and separated on a 4-15% gradient Tris-
glycine gel (Bio-Rad; 30 mA/gel, 45 min, 4°C), and then transferred to a nitrocellulose 
membrane (400 mA, 1.5 hours, 4°C). Following incubation with primary and secondary 
antibodies, bands were visualized using Enhanced Chemiluminesence reagent (ECL; Thermo 
Scientific). Membranes were exposed to x-ray film and analyzed using Image J software (NIH). 
All primary antibodies were generated in rabbit unless otherwise noted, and included: anti-A1R 
(1:500; Thermo Scientific), anti-TRPV1 (1:5000; Alomone, Jerusulem, Isreal), anti-pAkt (S473) 
(1:500; Cell Signaling, Danvers, MA), anti-total Akt (1:1000; Cell Signaling), anti-pPKA C-α 
(1:1000; Cell  Signaling), anti-total PKA (1:1000; Cell Signaling), anti-Cav2.2 (1:250; Origene, 
Rockville, MD), and mouse anti-α2 (1:1000; Sigma). All secondary antibodies were purchased 
from Santa Cruz, coupled to horseradish peroxidase and included goat anti-rabbit and donkey 
anti-mouse.  
Membranes were stripped using Restore Plus Western Blot Stripping Buffer (Thermo 
Scientific), followed by incubation with actin pre-conjugated to HRP (1:10,000; Abcam, 
Cambridge, MA) overnight at 4°C. Bands were visualized with ECL, membranes exposed to x-
ray film and analysis completed using Image J software (NIH).  
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Determination of cAMP concentration 
 Prior to sacrifice, nondiabetic and diabetic mice (8 weeks post-STZ; see Chapter 2) were 
injected with either i.t. Ado + ITU or i.t. CPA. Spinal cord and DRG were harvested at zero (no 
injection), 30 minutes and 5 hours following injection. Tissues were flash frozen in liquid 
nitrogen and stored at -80°C until use. A competitive binding ELISA (Enzo Life Sciences) was 
used to determine intracellular cAMP levels. Samples were analyzed per manufacturer’s 
protocol. Briefly, spinal cord and DRG were sonicated in 0.1 mM HCl (100 µl for spinal cord, 75 
µl for DRG). Following centrifugation at 600 x g for 10 min at 4°C, the protein concentration of 
the supernatant was determined using the Bradford assay (Bio-Rad). Standards were prepared by 
serial dilution using the supplied standard (2,000 pmol/mL cAMP) and used within one hour of 
preparation. Samples were diluted (1:20 for spinal cord; 1:10 for DRG) in 0.1mM HCl to fall 
within range of the standard curve. 100 µl of standards and samples in duplicate were loaded per 
well with appropriate solutions as indicated. Plates were incubated for 2 hours at room 
temperature with gentle shaking, washed three times with 400 µl of supplied wash buffer, and 
then incubated with substrate for one hour at room temperature without shaking. Upon stopping 
the reaction, the optical density of each plate was determined at 405 nm. Standard curves were 
generated using Prism software (Graphpad Inc.), and sample concentrations were determined. 
All samples were normalized to protein concentration. Samples that fell outside of the standard 
curve were eliminated from analysis.  
 
 
88 
 
Determination of mRNA expression levels 
 RNA was extracted from spinal cord, DRG and skin using TRI Reagent (Sigma) and 
RNeasy Mini Kit (Qiagen, Valencia, CA). Sample concentration and purity were determined 
using a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA). Complimentary DNA 
(cDNA) was synthesized from 0.5 µg total RNA using the iScript cDNA synthesis kit (Bio-Rad). 
qRT-PCR was performed using SsoFast Probes Supermix Kit (Bio-Rad). The primers used were 
as follows: 
 Cav2.2: Forward: 5’– CCTGATCGTCTACATGCTCTTC – 3’ 
 Reverse: 5’ – ATCAAATACTGACCCCTGC – 3’   
 Ribosomal L27: Forward: 5’ – ACAACCACCTCATGCCCACA – 3’   
 Reverse: 5’ – CTGGCCTTGCGCTTCAAA – 3’  
All reactions were performed in triplicate. Cav2.2 mRNA levels (spinal cord and DRG) were 
normalized to the ribosomal protein rL27. Raw PCR data was analyzed using LinRegPCR 
software (version 2012.3) to determine PCR efficiency values. Threshold cycle values for L27 
were subtracted from the samples, and the percentage of fold change from nondiabetic animals 
was calculated using the pfaffl method.  
Primary DRG cultures 
 Mice were overdosed with inhaled isoflurane (Pheonix, St. Joseph, MO), injected with 
150 µl of heparin (BD Biosciences, San Jose, CA) into the ventricle, and then transcardially 
perfused with ice-cold Ca2+/Mg2+ Hank’s Buffered Salt Solution (HBSS; Gibco). Lumbar DRG 
(L4-L6) were immediately dissected and placed in HBSS for further processing. Dissociation of 
neurons and culture preparations were prepared as previously described [145]. Briefly, DRG 
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were partially digested with papain (Worthington, Lakewood, NJ), followed by digestion with 
collagenase type II (Worthingon) and dispase (Roche, Basel, Switzerland). DRG were triturated 
through fire-polished glass Pasteur pipettes to dissociate neuronal cell bodies, and then plated on 
Poly-D-Lysine/Laminin coated glass coverslips (BD Biosciences) placed in 12-well culture 
plates. Neurons were allowed to adhere to the coverslips for 2-3 hours before incubation in F-12 
media (Life Technologies, Grand Island, NY) supplemented with 10% FBS and 
penicillin/streptomycin (50 U/mL) overnight at 37°C and 5% CO2 for imaging the next day. 
Calcium Imaging 
 Imaging experiments were performed as previously described [146]. Coverslips were 
incubated in HBSS with 5 mg/mL BSA (Sigma) and 2 µM fura-2 (Molecular Probes, Invitrogen) 
for 30 min at 37°C prior to mounting on an inverted Nikon microscope stage. The heated stage 
was maintained at a constant 30°C, and delivery of HBSS bath solution was controlled by a 
gravity flow system. Delivery of agonist solutions was accomplished using rapid-switching local 
perfusion system. Selection of neurons was made using a 480 nm filter and identified as regions 
of interest using NIS Elements software (Nikon Corporation). To check neuron viability, a brief 
5 second application of 30 mM K+ (high K+) was applied to the entire field. Neurons were 
stimulated with capsaicin and SDS following overnight incubation in media alone or media 
supplemented with 0.1 mM adenosine. Following application of high K+, neurons were allowed 
to recover for 5 min, after which 10 µM capsaicin was applied for 10 seconds. Stock capsaicin 
(10 mM) was prepared in 1-methyl-2-pyrrlidinone; 1 µM capsaicin was made fresh daily for use 
in experiments. After a 10 min recovery period, neurons were stimulated with 0.006% SDS in 
HBSS to obtain maximal calcium responses from each individual neuron for normalization 
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purposes [110]. Absorbance data at 340 and 380 nm were collected at one frame per second. The 
ratio of 340/380 nm was used to evaluate neuron responses. A peak response of of ΔF340/380 > 0.1 
was considered positive, and this ratio was used to calculate area under the curve using Excel 
macros.  
Statistical analysis 
Results were analyzed using the SPSS Statistics 20 software (IBM). Student’s t-tests and 
two-way analysis of variance (2-way ANOVA) with Fisher’s least significant difference (LSD) 
post-hoc analyses were performed, as denoted in the manuscript. A p-value less than 0.05 was 
considered significant. All data are presented as mean ± S.E.M. 
 
4. Results & Figures 
Downstream signaling following A1R activation by i.t. Ado + ITU or i.t. CPA.  
 As shown in Chapter 2, diabetic mice showed significant improvement in mechanical 
withdrawal thresholds following administration of either i.t. Ado + ITU or i.t. CPA. In the 
current study, several analyses were employed to determine which downstream pathways are 
activated following these treatment regimens. Activation of A1R is known to inhibit adenylyl 
cyclase activity, resulting in decreased production of cAMP and, consequently, decreased 
activation of PKA. A1R protein levels were evaluated to determine the effect of diabetes on 
protein expression. In the spinal cord, the concentration of A1R protein was trending towards a 
significant decrease (p = 0.056) in diabetic animals at eight weeks post-STZ induction of 
diabetes (Fig. 14A) compared to nondiabetic mice, however this difference was not considered 
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significant.  No significant differences in the concentration of A1R protein was seen in the DRG 
(Fig. 14B) between nondiabetic and diabetic mice.  
Competitive binding ELISAs were used to determine intracellular cAMP levels in the 
spinal cord and DRG of nondiabetic and diabetic mice following i.t. intervention. Following i.t. 
Ado + ITU, there were no significant differences in cAMP levels between nondiabetic and 
diabetic mice at any time point (Fig. 15A); however, an overall significant decrease in cAMP 
levels were seen in the spinal cord after 30 minutes compared to baseline, and this was trending 
towards significance at 5 hours compared to baseline (p = 0.064) (Fig. 15C). In the DRG, no 
significant differences in cAMP levels were seen between nondiabetic and diabetic mice at any 
time point (Fig. 15B), and cAMP levels at 30 min were significantly different from baseline (Fig. 
15D).  
Following administration of i.t. CPA, cAMP levels in the spinal cord at 5 hours post i.t. 
administration of CPA were significantly elevated compared to baseline in nondiabetic mice 
(Fig. 16A); no significant differences were seen in cAMP levels in between groups of diabetic 
mice at any time point. In diabetic mice at 5 hours post-delivery of i.t. CPA, levels of cAMP 
were significantly decreased compared to nondiabetic mice at the same time point (Fig. 16A). 
Overall, cAMP levels in the spinal cord following i.t. CPA were not significantly different at any 
time point (Fig. 16C). In the DRG, cAMP levels were not significantly different between 
nondiabetic and diabetic mice at any time point (Fig. 16B), nor were there any significant 
differences in overall cAMP levels (Fig. 16D) at any time point.  
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Figure 14. Protein levels of A1R are not affected by diabetes in the spinal cord or DRG. A) 
Following eight weeks of diabetes, A1R protein levels in the spinal cord were not significantly 
different in diabetic (DB) mice compared to nondiabetic (ND) mice (p > 0.05 vs. ND; t-test). B) 
Protein levels of A1R were not significantly different between ND and DB mice in the DRG (p > 
0.05 vs. ND; t-test). n = 7 – 9 mice per group.  
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Figure 15. cAMP production in the spinal cord and DRG following i.t. Ado + ITU. A, C) No 
significant differences in cAMP levels were seen between nondiabetic and diabetic mice at any 
time point (n = 4 – 6 mice per group), but an overall significant decrease in cAMP levels were 
seen in the spinal cord at 30 min following i.t. Ado + ITU compared to baseline (# p < 0.05 vs 
baseline; 2-way ANOVA with LSD post-hoc analysis). n = 9 – 10 mice per group. B, D) In the 
DRG, no differences in cAMP levels were detected between nondiabetic and diabetic mice at 
any time point (p > 0.05 vs. baseline; 2-way ANOVA with LSD post-hoc analysis). n = 4 – 6 
mice per group. Overall, cAMP levels in the DRG were not significantly decreased at 30 min or 
5 hours compared to baseline following i.t. administration of Ado + ITU (p > 0.05 vs. baseline; 
2-way ANOVA with LSD post-hoc analysis). n = 8 – 10 mice per group.  
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Figure 16. cAMP production in the spinal cord and DRG following i.t. CPA. A, C) cAMP 
levels in nondiabetic (ND) mice were significantly elevated at 5 hours compared to cAMP levels 
at 5 baseline (^ p < 0.05 vs. baseline; 2-way ANOVA with LSD post-hoc analysis). n = 4 – 6 
mice per group. Overall cAMP levels were not significantly different at any time point in the 
spinal cord (p > 0.05 vs. baseline; 2-way ANOVA with LSD post-hoc analysis). n = 9 – 10 mice 
per group. B, D) In the DRG, no differences in cAMP levels were detected between nondiabetic 
and diabetic mice at any time point (n = 4 – 5 mice per group), nor were there any significant 
differences in overall cAMP levels (p > 0.05 vs. baseline; 2-way ANOVA with LSD post-hoc 
analysis). n = 9 mice per group.  
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Many downstream events dependent on cAMP signaling are mediated through activation 
of PKA [137, 147]. Here, activation of PKA was evaluated in the spinal cord following i.t. 
administration of Ado + ITU or CPA. Representative blots are shown following delivery of i.t. 
Ado + ITU (Fig. 17A) or i.t CPA (Fig. 17B). Activation of PKA was determined by comparing 
phosphorylated PKA-Cα (p-PKA) to total PKA. Activation of PKA was not detected in the 
spinal cord following i.t. Ado + ITU (Fig. 17A) or i.t. CPA (Fig. 17A) between nondiabetic and 
diabetic mice at any time point, nor were there any differences in overall PKA activation 
following either treatment (Fig. 17C, D).  
 Activation of A1R has been associated with downstream activation of PI3K and Akt 
[148, 149]. Activation of Akt in the spinal cord was evaluated following administration of i.t. 
Ado + ITU and i.t. CPA. Representative blots are shown following i.t. administration of Ado + 
ITU (Fig. 18A) or CPA (Fig. 18B). Following delivery of i.t. Ado + ITU, no significant changes 
in the activation of Akt were detected between nondiabetic and diabetic mice (Fig. 18A), nor 
were any significant changes seen in overall Akt activation (Fig. 18C), at any time point. 
Interestingly, Akt activation in diabetic mice does appear to be elevated over nondiabetic mice at 
all time points, although this increase is not significantly different between nondiabetic and 
diabetic mice. Following administration of i.t. CPA, Akt activation at 30 min was significantly 
elevated compared to baseline within nondiabetic mice and within diabetic mice (Fig. 18B). 
Additionally, Akt activation in diabetic mice was significantly elevated at 5 hours compared to 
nondiabetic mice at this same time point. Furthermore, overall Akt activation at 30 min was 
significantly elevated compared to baseline (Fig. 18D).  
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Figure 17. Administration of i.t. Ado + ITU or i.t. CPA does not affect activation of PKA. 
Representative blots are shown for PKA activation in the spinal cord following i.t. Ado + ITU 
(A) and i.t. CPA (B). No significant changes in the activation of PKA following i.t. delivery of 
Ado + ITU (A, C) or i.t. CPA (B, D) were detected between nondiabetic (ND) and diabetic mice 
(A, B; n = 4 – 8 mice per group), nor were there any overall changes in activation of PKA (C, D; 
n = 9 – 16 mice per group) at any time point (p > 0.05 vs. ND; 2-way ANOVA with LSD post-
hoc analysis).  
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Figure 18. Akt activation in the spinal cord is elevated in diabetic mice following 
administration of i.t Ado + ITU and i.t. CPA. A) Activation of Akt in the spinal cord of 
diabetic (DB) mice was not significantly different compared to nondiabetic (ND) mice at any 
time point following administration of i.t. Ado + ITU (p > 0.05 vs. ND; 2-way ANOVA with 
LSD post-hoc analysis). n = 4 – 8 mice per group. C) Overall, activation of Akt was not 
significantly different at any time point (p > 0.05, 2-way ANOVA with LSD post-hoc analysis). 
n = 9 – 16 mice per group. B) Following administration of i.t. CPA, activation of Akt was 
significantly elevated at 30 min compared to baseline in both ND mice (^^^ p < 0.001 vs. ND; 2-
way ANOVA with LSD post-hoc analysis) and DB mice (&&& p < 0.001 vs. DB; 2-way ANOVA 
with LSD post-hoc analysis). Additionally, activation of Akt was significantly elevated in DB 
mice compared to ND mice at 5 hours (* p < 0.05 vs. ND 5 hours; 2-way ANOVA with LSD 
post-hoc analysis). n = 4 – 6 mice per group. D) Overall, activation of Akt at 30 min was 
significantly elevated compared to baseline (#### p < 0.0001 vs baseline; 2-way ANOVA with 
LSD post-hoc analysis). n = 9 – 10 mice per group.  
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Calcium channel expression and signaling.  
 Dysregulation of calcium channel expression and signaling has been associated with 
diabetic neuropathy and nerve injury [51, 150]. Specifically, the α2δ-subunit of calcium channels 
has been shown to be upregulated in the spinal cord and DRG following nerve injury [151]. 
Expression of the α2δ-subunit in the spinal cord and DRG was determined using western blot 
analysis. No change in α2-subunit protein levels were detected in the spinal cord (Fig. 19A) or 
DRG (Fig. 19B) between nondiabetic and diabetic mice. Activation of A1R is known to inhibit 
N-type calcium channels (Cav2.2) [77]. Therefore, Cav2.2 mRNA expression in the spinal cord 
and DRG were evaluated using qRT-PCR. Relative expression of Cav2.2 mRNA levels were not 
significantly different in diabetic mice compared to nondiabetic mice in the spinal cord (Fig. 
19C) or DRG (Fig. 19D).  
Calcium flux through TRPV1 is increased in diabetic mice.   
 Activation of A1R results in activation of PLC which can then cleave PIP2, and PIP2 has 
been shown to modulate TRPV1 activity, thus linking activation of A1R to modulation of 
TRPV1 signaling. Additionally, changes in TRPV1 expression and signaling have been 
implicated in diabetes-induced thermal changes [152-154]. TRPV1 protein levels were 
determined using western blot analysis in the spinal cord and DRG following eight weeks of 
STZ-induced diabetes. No significant differences in protein levels of TRPV1 were detected 
between diabetic and nondiabetic mice in the spinal cord (Fig. 20A) or DRG (Fig. 20B).  
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Figure 19. Diabetes does not affect calcium channel expression in the spinal cord or DRG. 
No significant changes in α2-subunit protein levels were detected using western blot analysis in 
the spinal cord (A; n = 8 mice per group) or DRG (B; n = 7 mice per group) of nondiabetic (ND) 
and diabetic (DB) mice (p > 0.05 vs. ND; t-test). Additionally, Cav2.2 mRNA concentration was 
not significantly different between ND and DB mice in the spinal cord (C) or DRG (D) (p > 0.05 
vs. ND; t-test). n = 6 mice per group. 
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Figure 20. Protein levels of TRPV1 are not affected by diabetes in the spinal cord or DRG. 
A) Protein levels of TRPV1 in the spinal cord were not different between nondiabetic (ND) and 
diabetic (DB) mice (p > 0.05 vs. ND; t-test). n = 8 – 9 mice per group. B) In the DRG, protein 
levels of TRPV1 were not significantly different in DB mice compared to ND controls (p > 0.05 
vs. ND; t-test). n = 7 – 8 mice per group.  
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Sowa et al. proposed that activation of A1R modulates TRPV1 activity through 
hydrolysis of PIP2 [110]. Thus, primary DRG cultures from nondiabetic and diabetic mice were 
incubated overnight with or without adenosine and then stimulated with capsaicin to determine if 
adenosine-mediated activation of A1R modulated capsaicin-induced calcium flux through 
TRPV1. Overnight incubation with adenosine significantly decreased the percentage of neurons 
that responded to capsaicin-mediated activation of TRPV1 (Fig. 21A). Area under the curve 
(AUC) analysis revealed that primary DRG cultures from diabetic mice had a significantly 
increased AUC compared to nondiabetic mice in the absence of adenosine (Fig. 21B). 
Furthermore, the AUC from primary DRG cultures from diabetic mice incubated overnight with 
adenosine was significantly decreased compared to the AUC from primary DRG cultures from 
diabetic media-only treated cultures, and this decreased AUC was not significantly different 
from control, nondiabetic media- and adenosine-treated cultures.  
 
5. Discussion 
In light of the behavioral outcomes discussed in Chapter 2, this study sought to determine 
what pathways were activated downstream of A1R that could influence mechanical sensitivity in 
painful diabetic neuropathy. To accomplish this task, a variety of molecular techniques were 
employed to investigate several of the second messenger pathways associated with activation of 
A1R, including cAMP production, activation of PKA, activation of Akt, and calcium channel 
expression and signaling. Levels of cAMP were not significantly different between diabetic and  
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Figure 8.  Calcium flux through TRPV1 in primary DRG cultures is increased in diabetic 
mice, and is restored by overnight incubation adenosine. A) In the presence of adenosine, the 
overall percentage of neurons that responded to stimulation with capsaicin was significantly 
decreased in both nondiabetic (ND) mice (^^ p < 0.01 vs. ND Media; 2-way ANOVA with LSD 
post-hoc analysis), and diabetic (DB) mice (&& p < 0.01 vs. DB Media; 2-way ANOVA with 
LSD post-hoc analysis) relative to cultures incubated with media only. B) Area under the curve 
(AUC) analysis revealed that DB mice had a significantly increased AUC in response to 
stimulation with capsaicin compared to ND controls (* p < 0.05 vs. ND Media; 2-way ANOVA 
with LSD post-hoc analysis). Overnight incubation with adenosine (Ado) reversed this increased 
AUC to ND control levels (&& p < 0.01 vs. DB Media; 2-way ANOVA with LSD post-hoc 
analysis).  
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nondiabetic mice; however, when groups were combined a significant decrease in cAMP levels 
in the spinal cord was observed following i.t. administration of Ado + ITU. At this same time, no 
activation of PKA was detected. Interestingly, Akt levels in diabetic mice were elevated 
compared to nondiabetic mice at all time points following treatment with i.t. Ado + ITU, 
although these differences were not statistically significant. Additionally, at 30 min following i.t. 
administration of CPA, a robust activation of Akt was observed in the spinal cord within 
nondiabetic mice and within diabetic mice. A significant increase in the activation of Akt in 
diabetic mice compared to nondiabetic mice was evident at 5 hours following i.t. delivery of 
CPA. Furthermore, these studies show that calcium signaling through TRPV1 is dysregulated in 
our model of painful diabetic neuropathy, and that treatment of primary DRG cultures overnight 
with adenosine is able to restore increased calcium flux through TRPV1 in diabetic mice to 
levels comparable to nondiabetic mice.  
cAMP production is decreased following central delivery of A1R agonists  
Classically, A1R activation is linked to inhibition of andenylyl cyclase through activation 
of Gαi, leading to decreased production of cAMP levels [138]. Results of studies shown here do 
not reveal any differences in cAMP levels between nondiabetic and diabetic mice, suggesting 
that the adenosine receptor itself is still able to signal properly in diabetic mice. However, when 
groups are combined, an overall decrease in cAMP levels at 30 min following i.t. administration 
of Ado + ITU compared to baseline was detected, suggesting that improvement in mechanical 
allodynia subsequent to A1R activation is mediated through inhibition of cAMP production and 
likely involves activation of A1R. Additionally, A1R protein levels in the spinal cord of diabetic 
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mice were trending towards a significant decrease. Taken together, these data suggest that it is 
altered receptor expression and activation, and not receptor function, which may underlie the 
development of painful diabetic neuropathy.  
 PKA is activated following increases in cAMP levels [155], which can phosphorylate and 
activate CREB. CREB activation regulates the expression of a number of genes, including c-fos 
and c-jun, both of which have been implicated in neuropathic pain conditions [156, 157]. 
Inhibition of CREB through i.t. injection of antisense oligonucleotides has been shown to 
alleviate mechanical allodynia in rats following partial sciatic nerve ligation [158]. The data 
presented here suggests that inhibition of cAMP production in the spinal cord, and therefore 
inhibition of activation of PKA and subsequent phosphorylation of CREB might prevent 
expression of c-fos and c-jun, providing a mechanism by which activation of A1R may 
contribute to alleviating mechanical allodynia in this rodent model of painful diabetic 
neuropathy. Future studies should explore CREB phosphorylation, as well as c-fos and c-jun 
expression in nondiabetic and diabetic mice, and following i.t. Ado + ITU treatment to evaluate 
the involvement of this signaling pathway and downstream mediators in A1R-mediated 
antinociception in painful diabetic neuropathy.  
 Following i.t. CPA, no significant differences in cAMP levels were detected at either 30 
min or 5 hours compared to baseline. However, when looking at group differences it should be 
noted that the significant differences seen between the time points in nondiabetic mice are likely 
a consequence of the method of analysis rather than actual physiological differences. There were 
many steps in the analysis that could contribute to this variability, such as overall protein 
concentration determination (each sample was normalized to individual protein concentration), 
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variability between duplicate samples on the plate, pipetting errors (samples were diluted to fall 
within range of the standard curve, pipetting of sample during plate loading), and small sample 
number. Sample sizes for all cAMP analyses were small (n = 4-6 per group, per time point, per 
treatment paradigm), and increases in sample number would likely eliminate these differences, as 
well as strengthen the differences observed in the Ado + ITU treated mice. Additionally, these 
time points were chosen for analysis because they correlate with observed behavioral outcomes. 
Future work should consider earlier time points (between baseline and 30 min) to capture early, 
rapid changes in cAMP levels [155]. 
 
Activation of Akt contributes to the antinociceptive actions of A1R activation 
 Akt is a key intracellular second messenger involved in a variety of cellular processes, 
such as cell growth, proliferation, metabolism, and it is activation of this signaling pathway that 
is attributed with a majority of the metabolic actions of insulin [159]. Phosphorylation of Akt is 
upregulated following activation of the insulin receptor, and Grote et al. recently reported 
blunted Akt signaling in the peripheral nervous system of ob/ob mice, suggesting that altered Akt 
signaling may contribute to the development of peripheral neuropathy [160]. Surprisingly, 
following i.t. delivery of CPA, significantly elevated levels of activated Akt were detected in 
nondiabetic mice and in diabetic mice, and this increased activation was significantly different at 
the 5 hour time point between nondiabetic and diabetic mice. Additionally, overall Akt activation 
was significantly elevated at 30 min compared to baseline following administration of i.t. CPA, 
suggesting that Akt signaling may be involved in mediating the antinociceptive benefits of 
activation of A1R.  
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Several studies have reported the role of Akt signaling in the maintenance of pain 
conditions, including recruitment of sodium channels in the development of CFA-induced 
inflammatory pain [161], opioid-induced tolerance and hyperalgesia in the spinal cord [162], and 
visceral pain conditions [163]. Conversely, others have reported that activation of PI3K/Akt 
signaling is involved in morphine-induced peripheral analgesia mediated by kappa opioid 
receptors [164, 165], as well as relief from neuropathic pain following treatment with the anti-
hypercholesterolemic drug atorvastatin [166], and that activation of PI3K/Akt provides a 
neuroprotective benefit in cortical neurons [149]. The data presented here support the later 
hypothesis, such that activation of Akt is involved in mediating the antinociceptive effects of i.t. 
Ado +ITU and i.t. CPA, providing new insight on the contribution of activation of Akt in A1R-
mediated antinociception.   
Voltage-gated calcium channels are a diverse group of channels involved in many aspects 
of cell signaling. Activation of A1R has been shown to inhibit P-, Q- and N-type calcium 
channels, and dysregulation of N-type calcium channels has been reported in diabetic rats [167, 
168]. Additionally, the α2δ-subunit of calcium channels has been reported to be upregulated 
following nerve injury, specifically in the DRG and in presynaptic nerve terminals [169, 170]. 
Dolphin et al. report that deletion of the α2δ-subunit gene delays development of mechanical 
sensitivity [171]. No significant changes in α2-protein levels in either the spinal cord or DRG 
were detected in diabetic mice compared to nondiabetic mice, nor were there any changes in 
Cav2.2 mRNA expression levels in the spinal cord or DRG between groups. However, there 
have been reports that Cav2.2 mRNA levels are actually down-regulated following sciatic nerve 
ligation [172]. Additionally, the experiments performed in this study were carried out at a 
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terminal time point, at eight weeks following STZ-induction of diabetes, when diabetic mice 
have reached a minimum threshold in terms of their mechanical sensitivity. There is likely 
temporal regulation of calcium gene and protein expression and the terminal time points at which 
these experiments were performed were beyond the window in which to capture changes in 
relative expression. Future experiments should address the effect of time on differential 
regulation and expression of calcium channels.  
Diabetic male A/J mice do not develop changes in thermal sensitivity (unpublished data) 
so it is not surprising that there were no changes in TRPV1 protein expression levels between 
nondiabetic and diabetic mice. Interestingly, it appears that TRPV1 may be slightly decreased in 
the DRG of diabetic mice, however, this difference was not statistically significant. Indeed, 
Hong and Wiley report that TRPV1 expression is decreased in the DRG of diabetic rats when 
using whole cell homegnates for western blot analysis, but was enriched in the plasma membrane 
[154]. Despite the lack of thermal hyperalgesia evident in the current model of painful diabetic 
neuropathy, alterations in calcium flux through the TRPV1 channel following activation with 
capsaicin were significantly increased in primary DRG cultures from diabetic mice. This 
suggests that altered TRPV1 signaling contributes to dysregluated calcium homeostasis in this 
model system and may contribute to the development of painful neuropathy. Furthermore, 
overnight treatment of primary DRG cultures from diabetic mice with adenosine blunts this 
altered signaling, strengthening the argument that activation of A1R inhibits TRPV1 activity, 
presumably through PLC-mediated cleavage of PIP2, providing a mechanism by which calcium 
signaling can be modulated in vivo.  
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Conclusions 
 Several downstream signaling pathways are associated with activation of A1R. The 
experiments performed in this chapter were done in an attempt to identify those pathways which 
may be involved in mediating the antinociceptive behavioral outcomes observed in Chapter 2 
following i.t. administration of Ado + ITU and i.t. CPA. No changes in cAMP levels were 
detected between diabetic and nondiabetic mice following either i.t. Ado + ITU or i.t. CPA, 
suggesting that diabetes does not affect the ability of A1R to signal properly. Additionally, 
activation of PKA was not observed, suggesting that inhibition of cAMP-mediated activation of 
PKA was prevented following these pharmacological interventions, and may suggest a 
mechanism by which activation of A1R contributes to alleviating mechanical sensitivity in 
painful diabetic neuropathy. Surprisingly, a robust activation of Akt in the spinal cord was 
observed following i.t. administration of CPA, and this increased activation was significantly 
different between nondiabetic and diabetic mice at 5 hours following delivery of CPA. This 
suggests that the PI3K/Akt second messenger pathway may be involved in A1R-mediated 
antinociception in painful diabetic neuropathy. Finally, increased calcium flux through neurons 
in primary DRG cultures from diabetic mice in response to the TRPV1 agonist capsaicin was 
observed, and this heightened response was blunted by overnight incubation with adenosine, 
suggesting that adenosine can regulate calcium homeostasis and the mechanism by which the 
occurs by be through activation of A1R.  
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CHAPTER 4 
Peripheral delivery of specific A1R agonist reveals a novel mechanism for the treatment of 
painful diabetic neuropathy 
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1. Abstract 
Current strategies for the treatment of painful diabetic neuropathy primarily rely on the 
use of oral medications. However, these agents come with varying efficacy between individuals 
and carry significant risk of systemic adverse effects. Thus, there has been a recent impetus to 
move away from systemic (oral) treatment regimens and move towards peripheral routes of 
delivery (topical treatment) that minimize risk of systemic adverse effects. In this chapter, we 
show that A1R is expressed in the hind paw skin of nondiabetic and diabetic mice, and that 
diabetes does not affect the protein levels of this receptor. Additionally, we show that peripheral 
(intraplantar) delivery of a specific and selective A1R agonist, CPA, significantly reverses 
mechanical allodynia in diabetic mice. This shows that peripheral administration of A1R-specific 
agonists is effective at alleviating signs of mechanical allodynia associated with painful diabetic 
neuropathy, and that further development of peripheral routes of delivery can provide a novel 
therapeutic treatment option for individuals suffering from painful diabetic neuropathy.  
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2. Introduction 
Current treatment options for painful diabetic neuropathy are limited to symptomatic 
treatment, have variable efficacy, and come with significant risk of side effects [9, 17, 114]. 
Therapies currently in use for the management of painful diabetic neuropathy include 
antidepressants (ex: tricyclic antidepressants and selective serotonin-norepinephrine reuptake 
inhibitors), opioids (ex: oxycodone, tramadol), antiepileptic drugs (ex: gabapentin, pregabalin), 
and topical agents (ex: capsaicin cream, lidocaine cream). Notably, none of these treatment 
options are aimed at the pathogenetic mechanisms thought to underlie the development of 
painful diabetic neuropathy. To date, the only proven disease modifying intervention effective in 
delaying the progression of diabetic neuropathy is tight glycemic control [9, 10, 27, 28]. 
Several pathogenetic treatment options are under investigation, but none are licensed for 
use in the United States and few have made it successfully through clinical trials [9, 33, 117]. 
One such treatment option, Epalrestat, an aldose reductase inhibitor, is currently licensed for use 
in Japan and India. Epalrestat works by inhibiting the enzyme aldose reductase, thus decreasing 
the production of sorbitol and minimizing osmostic stress that is believed to contribute to nerve 
damage [30]. Another treatment option aimed at decreasing oxidative stress that is present in 
diabetic neuropathy is the use of antioxidants, such as α-lipoic acid. This has shown limited 
success in the United States at reducing pain, praresthesias and numbness associated with painful 
diabetic neuropathy, although no significant improvement in clinical outcomes were evident in 
two separate clinical trials [35, 36]. Recently, adenosine receptors have gained attention as a 
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possible target for modulating pain associated with inflammatory and neuropathic pain 
conditions [81, 173, 174].  
Human studies investigating the efficacy of adenosine at alleviating symptoms of pain 
have shown positive results. One study reports improvement in spontaneous and evoked pain 
while receiving intravenous (i.v.) infusion of adenosine [87]. Another study reports improvement 
in tactile pain thresholds [89], and yet another study reports a decrease in the area of mechanical 
allodynia and evoked pain to mechanical stimuli following intrathecal (i.t.) administration of 
adenosine [88]. Collectively, these results suggest that adenosine may have beneficial effects in 
humans for treating pain conditions; however, none of these trials evaluated the effect of 
adenosine on painful diabetic neuropathy. Furthermore, use of i.v. or i.t. infusion for the delivery 
of pain medication is not a suitable method of delivery for daily maintenance of pain symptoms 
for individuals living with painful diabetic neuropathy.  
Use of oral medications, as well as i.v. or i.t. delivery of therapeutics, comes with 
significant risk of systemic adverse effects. Thus, there is a recent impetus to move away from 
oral medications towards the exploration the use of topical delivery methods for treating painful 
conditions [45]. In this study, we determined if peripheral delivery of A1R agonists could 
activate A1R-mediated antinociceptive pathways to alleviate signs of mechanical allodynia in a 
rodent model of painful diabetic neuropathy.  
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3. Experimental Procedures 
Animals 
All experiments were approved by the University of Kansas Medical Center Institutional 
Animal Care and Use Committee. Inbred male A/J mice were obtained from Jackson 
Laboratories at 7 weeks of age, and were induced with diabetes at 8 weeks of age. All mice were 
housed in the Laboratory Animal Resources building, had ad libitum access food and water, and 
maintained on a 12 hour light/dark cycle. All mice were sacrificed at 16 weeks of age.  
Streptozocin induction of diabetes 
8 week old male A/J mice were injected with Streptozocin (STZ; Sigma, St. Louis, MO) 
to induce type 1 diabetes. Mice were fasted for 3 hours before and after injections, for a total 
fasting time of 6 hours. Injections were spread over 2 days, with the first dose (day 1) at 85 
mg/kg and the second dose (day 2) at 65 mg/kg. Solutions were made fresh immediately prior to 
injection and STZ was dissolved in ice cold 10 mM sodium citrate buffer with 0.9% NaCl at pH 
4.5, and then filter sterilized. Control, nondiabetic, mice were injected with sodium citrate buffer 
only. Animals that did not reach hyperglycemia (blood glucose >230 mg/dL) within one week 
following initial injections were re-injected with either 85 mg/kg STZ (blood glucose <180 
mg/dL) or 65 mg/kg STZ (blood glucose 181-230 mg/dL). Mice that failed to reach 
hyperglycemia were excluded from the study.  
Behavioral analysis 
Prior to behavioral testing, mice were acclimated to the behavior facility and equipment 
for a minimum of 2 days. On test days, mice were placed in the behavior facility and allowed to 
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acclimate to the environment for at least 30 minutes. Mice were then acclimated on the behavior 
apparatus for 20 to 30 minutes prior to initiating testing. Mice were placed in individual clear 
plastic cages on top of a wire mesh grid that allowed access to their hind paws for the duration of 
the analysis. Mechanical withdrawal thresholds using von Frey monofilaments were measured 
weekly to track progression of neuropathy phenotype using the up-down method to determine 
fifty percent withdrawal thresholds [121]. Tests for mechanical sensitivity following intraplantar 
(i.pl.) injections were performed at 30 min, 1.5 hours, 3 hours and 5 hours following injection. 
Drugs and Drug Administration 
Adenosine (Ado), AMP and CPA (direct A1R agonist) were purchased from Sigma; 
5’iodotubercidin (ITU; adenosine kinase inhibitor) was purchased from Enzo Life Sciences. 
AMP, Ado, and CPA were dissolved in 0.9% saline at pH 7.4. AMP was delivered at a 
concentration of 200 nmol/10 µl [104]; Ado and CPA were delivered at 10 nmol/10 µl  [122, 
123]; hPAP was dissolved in saline and delivered at a dose of 250 mU/10 µL [100]. ITU was co-
administered with Ado or AMP at a concentration of 5 nmol/10 µL [124]. Intraplantar (i.pl) 
injections (AMP + ITU, Ado + ITU, CPA) were performed using a 31 gauge, ½” insulin syringe 
(BD Biosciences) between the distal volar footpads of the right hindpaw [175].  
Western Blot Analysis 
At sacrifice, spinal cord and DRG were flash frozen in liquid nitrogen and stored at -
80°C until processing. Tissues were sonicated in cell extraction buffer (Invitrogen, Carlsbad, 
CA) containing 55.5 µl/mL protease inhibitor cocktail (Sigma, St. Louis, MO), 200 mM Na3VO4 
and 200 mM NaF for 60 min on ice with gentle vortexing every 10 min for protein extraction. 
Following centrifugation at 7000 rpm for 10 min at 4°C, the protein concentration of the 
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supernatant was determined using the Bradford assay (Bio-Rad, Hercules, CA). Samples were 
boiled with lane marker reducing sample buffer (Thermo Scientific, Waltham, MA) and stored at 
-20°C until use. Equal amounts of protein were loaded and separated on a 4-15% gradient Tris-
glycine gel (Bio-Rad; 30 mA/gel, 45 min, 4°C), and then transferred to a nitrocellulose 
membrane (400 mA, 1.5 hours, 4°C). Following incubation with primary and secondary 
antibodies, bands were visualized using Enhanced Chemiluminesence reagent (ECL; Thermo 
Scientific). Membranes were exposed to x-ray film and analyzed using Image J software (NIH). 
The primary antibody used was rabbit anti-A1R (1:500; Thermo Scientific), and the secondary 
antibody, coupled to horseradish peroxidase, was goat anti-rabbit (Santa Cruz). Bands were 
visualized with ECL, membranes exposed to x-ray film and analysis completed using Image J 
software (NIH).  
Determination of A1R mRNA concentration  
 RNA was extracted from spinal cord, DRG and skin using TRI Reagent (Sigma) and 
RNeasy Mini Kit (Qiagen, Valencia, CA). Sample concentration and purity were determined 
using a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA). Complimentary DNA 
(cDNA) was synthesized from total RNA using the iScript cDNA synthesis kit (Bio-Rad). qRT-
PCR was performed using SsoFast Probes Supermix Kit (Bio-Rad). The primers used were as 
follows: 
 A1R: Forward: 5’ – TGTGCCCTTAAATGTACTGG – 3’  
 Reverse: 5’ – TCTGTGGCCCAATGTTGATAAG – 3’  
 GAPDH: Forward: 5’ – AGGTCGGTGTGAACGGATTTG – 3’  
 Reverse: 5’ – TGTAGACCATGAGTTGAGGTCA – 3’  
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All reactions were performed in triplicate. A1R mRNA levels (skin) were normalized to 
GAPDH. Raw PCR data was analyzed using LinRegPCR software (version 2012.3) to determine 
PCR efficiency values. Threshold cycle values for L27 were subtracted from the samples, and 
the percentage of fold change from nondiabetic animals was calculated using the pfaffl method.  
Statistical analysis 
Results were analyzed using the SPSS Statistics 20 software (IBM). Student’s t-tests and 
two-way repeated measures analysis of variance (2-way RM-ANOVA) with Fisher’s least 
significant difference (LSD) post-hoc analyses were performed, as denoted in the manuscript. A 
p-value less than 0.05 was considered significant. All data are presented as mean ± S.E.M. 
 
4. Results & Figures 
A1R is expressed in the hind paw skin of mice  
The concentration of A1R mRNA and protein levels in the skin was evaluated to 
determine if this important antinociceptive pathway was accessible from the periphery. Analysis 
of mRNA expression levels in the skin revealed that A1R is detectable in the hind paw; however, 
there were no differences in relative expression of A1R mRNA levels between nondiabetic and 
diabetic mice (Fig. 22A). Protein expression levels were also evaluated, and no significant 
differences were detected between nondiabetic and diabetic mice (Fig. 22B).  
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Figure 22. A1R is expressed in the hind paw of mice. A) Expression of A1R mRNA was 
detected in the hind paw skin of nondiabetic (ND) and diabetic (DB) mice, but there was no 
difference in the relative expression levels of A1R mRNA between the two groups (p > 0.05 vs. 
ND; t-test). B) Protein expression of A1R not significantly different between ND and DB mice (p 
> 0.05 vs. ND; t-test). n = 7 mice per group.  
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Peripheral delivery of an A1R agonist reduces mechanical hypersensitivity. 
Because A1R is expressed in the skin, we hypothesized that peripheral delivery of A1R 
agonists may be able to activate this antinociceptive pathway following a peripheral route of 
administration. Protein expression of NT5E, but not PAP, has been detected in the hind paw skin 
of mice [104]. Thus, i.pl. AMP + ITU was tested to determine if endogenous enzymatic 
hydrolysis of AMP was sufficient to activate peripheral A1R. Unfortunately, i.pl. administration 
of  AMP + ITU was not effective at alleviating mechanical allodynia in diabetic mice (Fig. 23).  
To bypass enzymatic hydrolysis, i.pl. Ado + ITU was tested to determine if direct 
activation of A1R could alleviated mechanical allodynia in diabetic mice. This, too, failed to 
alleviate mechanical allodynia in diabetic mice; rather, diabetic mice remained consistently 
allodynic throughout the duration of the study (Fig. 24). Diabetic mice treated with i.pl. Ado + 
ITU had significantly reduced withdrawal thresholds compared to diabetic vehicle treated mice 
at 30 min and 1.5 hours following treatment. Interestingly, nondiabetic mice treated with i.pl. 
Ado + ITU were not significantly different from diabetic mice treated i.pl. Ado + ITU at 30 min 
and 1.5 hours, but were significantly different at 3 hours post-treatment and trending towards 
significantly different at 5 hours (p = 0.065) post-treatment.  
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Figure 23. Peripheral delivery of AMP + ITU does not alleviate mechanical allodynia in 
diabetic mice. Diabetic (DB) mice did not show any recovery in their mechanical withdrawal 
threshold following administration of i.pl. AMP + ITU (AMP, 200 nmol/10 µl; ITU, 5 nmol/10 
µl) compared to DB vehicle treated mice (p > 0.05 vs. DB Veh; 2-way RM-ANOVA with LSD 
post-hoc analysis). n = 5-7 mice per group. 
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Figure 24. Administration of i.pl. Ado + ITU did not reverse mechanical allodynia in 
diabetic mice. Diabetic (DB) mice treated with i.pl Ado + ITU (Ado, 10 nmol/10 µl; ITU, 5 
nmol/10 µl) remained consistently allodynic throughout the duration of the experiment, and had 
significantly reduced withdrawal thresholds compared to DB vehicle treated mice at 30 min and 
1.5 hours post-treatment (* p < 0.05 vs. DB Veh; 2-way RM-ANOVA with LSD post-hoc 
analysis). Nondiabetic (ND) mice treated with i.pl. Ado + ITU were not significantly different 
from DB i.pl. Ado + ITU (DB Ado) treated mice at 30 min and 1.5 hours following treatment, 
but were significantly different at 3 hours (& p < 0.05 vs. DB Ado; 2-way RM- ANOVA with 
LSD post-hoc analysis). n = 5 – 8 mice per group.  
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Finally, the direct A1R agonist, CPA, was given to determine if specific activation of 
A1R had any effect on mechanical allodynia. Surprisingly, i.pl. CPA was able to transiently 
reverse mechanical sensitivity in diabetic mice for up to 3 hours compared to baseline and 
diabetic vehicle treated mice (Fig. 25). Furthermore, nondiabetic mice that received i.pl. CPA 
displayed mechanical withdrawal thresholds that were significantly elevated compared to 
nondiabetic vehicle treated mice for up to 3 hours, similar to diabetic CPA-treated mice.  
 
5. Discussion 
In this study, the efficacy of peripheral delivery of A1R agonists was evaluated. Results 
show that direct peripheral activation of A1R by the selective agonist, CPA, provided relief of 
mechanical allodynia in diabetic mice for up to 3 hours. Furthermore, nondiabetic mice that 
received the active compound had significantly elevated mechanical withdrawal thresholds over 
nondiabetic mice that received vehicle only. These results show that peripheral activation of 
A1R-mediated antinociceptive pathways may provide a novel mechanism for treatment of 
painful diabetic neuropathy that bypasses traditional systemic (oral) delivery routes.  
 
Adenosine in the periphery is pro-nociceptive  
 Previous studies have shown that direct administration of adenosine to the hind paw of 
rats results in cutaneous hyperalgesia and decreased paw withdrawal thresholds, a result likely 
mediated through activation of A2AR and increased cAMP production [176]. In this study,  
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Figure 25. Peripheral delivery of the A1R agonist, CPA, significantly reverses mechanical 
allodynia in diabetic mice. Intraplantar administration of CPA (10 nmol/10 µl) significantly 
reversed mechanical allodynia in diabetic (DB) mice compared to baseline (## p < 0.01 vs. DB 
CPA; 2-way RM-ANOVA with LSD post-hoc analysis) and compared to DB vehicle treated 
mice (** p < 0.01 vs. DB Veh; 2-way RM-ANOVA with LSD post-hoc analysis). Additionally, 
nondiabetic mice (ND) that received i.pl. CPA had significantly increased withdrawal thresholds 
compared to ND vehicle treated mice for up to 3 hours (^^ p < 0.01 vs. ND Veh; 2-way RM-
ANOVA with LSD post-hoc analysis). n = 4 – 5 mice per group.  
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diabetic mice that received peripheral (i.pl.) delivery of AMP + ITU did not show any recovery 
in mechanical withdrawal thresholds, suggesting that indirect activation of A1R by NT5E-
mediated hydrolysis of AMP was insufficient to activate this antinociceptive pathway. 
Additionally, all nondiabetic mice, including both AMP-treated and vehicle-treated mice, 
displayed significantly reduced withdrawal thresholds compared to baseline. This suggests that 
the injection itself may have caused significant sensitivity as evidenced by decreased withdrawal 
thresholds in nondiabetic vehicle-treated mice, and further supports the conclusion that indirect 
activation of A1R is ineffective at alleviating mechanical sensitivity. 
 Further evidence that administration of adenosine in the periphery is pro-nociceptive is 
seen in nondiabetic mice that received i.pl. Ado + ITU. These mice display a slight decrease in 
their mechanical withdrawal thresholds that were not significantly different from diabetic mice 
who also received i.pl. Ado + ITU. Diabetic mice that received i.pl. Ado + ITU remained 
consistently allodynic throughout the duration of the study, whereas diabetic mice that received 
only the vehicle showed improvement in their withdrawal thresholds, although this was not 
significantly different from baseline. Additionally, nondiabetic mice that received only the 
vehicle had no change in their withdrawal thresholds, supporting the notion peripheral 
administration of adenosine increased mechanical sensitivity in nondiabetic mice. Futures studies 
should investigate the contribution of other peripherally located adenosine receptors, specifically 
A2AR, to the development of mechanical sensitivity following peripheral delivery of adenosine.  
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Peripheral delivery of a direct A1R agonist alleviated mechanical allodynia in diabetic mice 
Previous studies have shown that peripheral delivery of the A1R agonist, CPA, can 
inhibit the peripheral pro-nociceptive effects of adenosine, A2AR activation and PGE2-mediated 
hyperalgesia is the rat hind paw [176, 177]. The results presented here directly support this 
theory, as evidenced by a reversal of mechanical withdrawal thresholds in diabetic mice treated 
with i.pl. CPA. Additionally, nondiabetic mice that received i.pl. CPA displayed mechanical 
withdrawal thresholds that were significantly elevated over nondiabetic mice that received only 
the vehicle. It should be noted that in this study, nondiabetic vehicle-treated mice developed 
decreasing withdrawal thresholds throughout the experiment which could be due to several 
mechanisms, including learned behavior in the absence of an analgesic on board and in the face 
of repeated stimulation, inflammatory pain as a result of the injection itself, or a behavioral 
anomaly in this specific experimental group.  
Recently, there has been an impetus to move away from oral medications for pain 
management and a push towards topical administration of analgesics to mitigate systemic 
adverse effects [45, 178, 179], which is one of the major limitations of current treatment options 
[17, 114, 117]. There have been a number of human studies demonstrating efficacy in using 
adenosine as a potential analgesic [88, 173, 180]. Many of these studies involve either i.v. or i.t. 
administration of adenosine, but this, too, has limitations including headache and transient low 
back pain at the sight of injection [87, 88, 173, 180]. These studies provide further evidence that 
peripheral delivery of a direct A1R agonist can provide analgesic relief of pain-like symptoms in 
a mouse model of painful diabetic neuropathy. 
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Conclusions 
The experiments performed in this chapter were done in an attempt to translate the 
encouraging outcomes seen following i.t. administration of A1R agonists into a potential therapy 
for individuals suffering from painful diabetic neuropathy. Indirect hydrolysis of the substrate for 
NT5E, AMP, was ineffective at activating A1R-mediated antinociceptive pathways, nor was 
peripheral delivery of adenosine. In fact, peripheral delivery of adenosine revealed outcomes that 
suggest adenosine in the periphery may have pro-nociceptive actions, a result opposite of the 
goals of this study. Surprisingly, peripheral delivery of the specific A1R agonist, CPA, 
effectively reversed mechanical allodynia in diabetic mice. This suggests that directly targeting 
A1R with agonists specific for this receptor may provide a novel mechanism to alleviate 
mechanical allodynia, warranting further investigation into the efficacy of topical analgesics that 
activate A1R for treating painful diabetic neuropathy and other neuropathic pain conditions.  
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CHAPTER 5 
 
General Discussion and Conclusions  
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Purinergic signaling has been studied for several decades, and significant advances have 
been made towards the understanding of adenosine and adenosine receptors in normal 
physiological and pathophysiological processes, and the potential for these signaling pathways to 
be utilized as targets for treatment options. Activation of A1R has been explored as a potential 
therapeutic target due to its antinociceptive effects, and it is this feature that was exploited in this 
dissertation to determine the role A1R in modulating pain sensation in a rodent model of painful 
diabetic neuropathy. Through a series of in vitro and in vivo experiments, results contained 
herein show that diabetes significantly affects the ability of ectonucleotidases to generate 
extracellular adenosine, but that this important antinociceptive pathway is still functional and can 
be activated through central and peripheral delivery methods to alleviate signs of mechanical 
allodynia in diabetic mice.  
Diabetes affects generation of extracellular adenosine  
 Extracellular adenosine primarily arises from two sources: release from intracellular 
stores through equilibrative nucleotide transporters in the cell membrane, or through extracellular 
hydrolysis of adenine nucleotides by ectonucleotidases. Extensive studies have identified PAP 
and NT5E as the primary enzymes in the spinal cord and DRG responsible for hydrolyzing 
AMP, and these two enzymes are primarily located on small- and medium-diameter, putative 
nociceptive neurons, placing them in prime location to modulate nociceptive neurotransmission 
[100, 103-105]. Studies using A1R knockout mice (A1R-/-) provided some of the first in vivo 
evidence that A1R has a physiological role in modulating nociception [79, 86]. These studies 
also revealed decreased inhibition of excitatory glutamatergic signaling, evidenced by a lack of 
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inhibition of field excitatory postsynaptic potentials in the hippocampus of A1R-/- mice. 
Interestingly, mice heterozygous for A1R (A1R+/-) showed loss of inhibition that was 
proportional to the number of A1R receptors expressed. Furthermore, administration of i.t. hPAP 
and recombinant NT5E were ineffective at alleviating mechanical allodynia and thermal 
hyperalgesia in A1R-/- mice following induction of inflammatory or neuropathic pain models, 
confirming that the antinociceptive effects of adenosine generated through hydrolysis of AMP by 
ectonucleotidases is mediated through activation of A1R [100, 124]. Subsequent studies have 
confirmed that adenosine modulates nociceptive neurotransmission in the substantia gelatinosa 
through control of glutamate release from spinal interneurons, thus regulating excitatory synaptic 
transmission [112, 118, 120]. 
At eight weeks post-STZ induction of diabetes, male A/J diabetic mice display significant 
mechanical allodynia as evidenced by significantly decreased mechanical withdrawal thresholds 
compared to nondiabetic mice, indicative of a pain-like phenotype. At this same time point, we 
show for the first time that diabetes significantly affects the endogenous hydrolytic capacity of 
ectonucleotidases in the DRG at physiological pH (7.4) and acidic pH (5.6) to generate 
adenosine from AMP, suggesting that altered adenosine production and loss of activation of A1R 
may contribute to the development of painful diabetic neuropathy in this model system. At this 
same time point, A1R protein expression levels remain unchanged in the DRG of diabetic mice 
compared to nondiabetic mice. However, in the spinal cord, A1R protein expression levels were 
trending towards a significant decrease in diabetic mice compared to nondiabetic controls, yet 
there was no change in the hydrolytic capacity of ectonucleotidases in the spinal cord. Thus, in 
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the DRG, A1R expression levels likely remain similar to control levels due to decreased 
bioavailability of adenosine locally. Given that ectonucleotidase activity in the spinal cord of 
diabetic mice is comparable to control levels, an overall decrease in adenosine receptor 
expression could influence nociceptive tone in the central nervous system through decreased 
activation of A1R as a result of down-regulation of the receptor. Collectively, these data suggest 
that decreased adenosine production in the peripheral nervous system (DRG) coupled with fewer 
receptors available for activation in the central nervous system (spinal cord) could have a major 
impact on pain transmission, manifested as mechanical allodynia in our model of painful diabetic 
neuropathy.  
To further investigate the role of ectonucleotidases and their contribution to the 
development of painful diabetic neuropathy, measuring in vivo levels of adenosine would 
provide direct evidence regarding fluctuations in endogenous production of adenosine in the 
setting of diabetes. Street et al. were able to measure in real-time the production of adenosine 
following application of 100 µM AMP to the dorsal horn of spinal cord slices from mice using 
fast-scan voltammetry [105]. This method would add further evidence that ectonucleotidase 
activity is altered as a consequence of diabetes, and could likely be adapted to measure adenosine 
production in the DRG. Alternatively, high performance liquid chromatography or tandem mass 
spectroscopy could provide significant insight into the levels of adenosine in the spinal cord and 
DRG in diabetic and nondiabetic mice [181-183]. This could also be used to measure adenosine 
production following treatment of diabetic mice with i.t. hPAP and i.t. AMP + ITU.  
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The other side of the adenosine-A1R-antinociception spectrum is the contribution of P2 
receptors (P2X and P2Y) to pain sensation and transmission, which are activated primarily by 
ATP and ADP [68, 184, 185]. ATP-mediated signaling is well documented in the transduction of 
painful stimuli, and numerous studies have identified P2X3 as one of the main receptors involved 
in this process [185-187]. Interestingly, mRNA levels of P2X3 in the DRG are elevated in STZ-
induced diabetic rats, and diabetic rats display signs of mechanical allodynia [187], and 
inhibition of P2X3 has been shown to alleviate mechanical allodynia in diabetic rats [188]. Not 
surprisingly, PAP and NT5E are also located on this same neuronal population [100, 103, 104], 
strengthening the argument that the role of these enzymes is to mitigate pro-nociceptive 
signaling induced by ATP. 
More recently, P2X4 has been under investigation for its potential role in the 
development of mechanical allodynia. Tsuda et al. showed that P2X4 receptor expression is 
upregulated in activated microglia following nerve injury rats [71]. Inhibitors of both P2X3 and 
P2X4 were effective at reversing mechanical allodynia in these models, suggesting another 
potential target for the treatment of painful diabetic neuropathy. Diabetes is associated with 
increased inflammation, and ATP-mediated signaling is increased under inflammatory conditions 
[127, 189]. Taken together, it is plausible to suggest that in diabetes the scale is tipped towards a 
pro-nociceptive state. Up-regulation of P2X receptors, coupled with decreased hydrolysis of 
AMP and generation of adenosine, results in decreased activation of A1R and the downstream 
antinociceptive pathways, thus allowing for signaling propagation through pro-nociceptive P2X 
receptors.   
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Additionally, P2Y receptor-mediated signaling is also involved in pain transmission. 
These receptors are activated primarily by ATP or ADP, although some can also respond to UTP 
or UDP [72, 184]. P2Y1 receptors were shown to be expressed in a majority of small-diameter 
neurons, specifically neurons that express IB4 and P2X3 [190], and P2Y1 is necessary in the 
development of CFA-induced inflammatory pain [191]. Additionally, P2Y12, P2Y13 and P2Y14 
are expressed on small-diameter, putative nociceptive neurons, and activation of these receptors 
via ADP is involved in mitigating CFA-induced inflammatory pain [191], further adding to the 
complexity of nociceptive neurotransmission and inhibition. Much less is known about the 
involvement of P2Y receptors in pain transmission and inhibition compared to P2X receptors, 
and even less is known about the effect of diabetes on P2Y receptor expression and function. 
Evaluation of P2Y receptor expression and function in the context of diabetes would add a 
substantial body of knowledge to the field of purinergic signaling in general, particularly in the 
context of painful diabetic neuropathy, and would aid in our understanding of the role of 
purinergic signaling in the development and inhibition of painful diabetic neuropathy.   
Central delivery of A1R agonists can alleviate mechanical allodynia in painful diabetic 
neuropathy 
Of the four recognized adenosine receptors, A1R is attributed with having antinociceptive 
benefits. Indeed, this has been documented in numerous studies exploring the role of A1R 
activation in mitigating pain transmission in rodent models [131-133, 192-194]. The data 
contained herein adds another piece to the puzzle by showing that central activation of A1R is 
effective at alleviating mechanical allodynia in a rodent model of painful diabetic neuropathy. 
144 
 
Most studies investigating the role of A1R-mediated antinociception use artificial methods to 
induce nociception using animal pain models, such as induction of inflammatory pain by CFA, 
carrageenan or formalin, or surgical methods, such as sciatic nerve ligation or chronic 
constriction injury, to induce neuropathic pain. Our model consistently results in increased 
mechanical sensitivity as the course of this chronic, systemic disease progresses. Furthermore, 
most studies show an effect of A1R activation on alleviating thermal hyperalgesia, and far fewer 
studies explore the contribution of A1R activation and modulation of mechanical sensation. The 
work presented in this dissertation clearly demonstrates that A1R activation does have an effect 
on mechanical sensation, and that central activation of this receptor is effective at alleviating 
mechanical sensitivity in diabetic mice.  
To truly confirm that the antiallodynic effects seen in response to i.t. administration of 
AMP + ITU, Ado + ITU and CPA are mediated through A1R, future studies should incorporate 
the use of A1R-/- mice back-bred onto an A/J background. A1R-/- mice are commercially available 
from Jackson Laboratories on a C57Bl/6 background. Use of conditional (doxycycline-inducible 
deletion) or selective (peripheral nervous system specific Cre/lox activated elimination) A1R 
knockout mice could provide additional insight into the contribution of A1R-mediated 
antinociception in the central and/or peripheral nervous system. Additionally, future in vitro and 
in vivo experiments should include the use of antagonists to A1R, such as the modified xanthine 
derivative, DPCPX, to add further evidence that the behavioral outcomes presented in this body 
of work are indeed mediated through activation of A1R.  
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A small number of studies have been conducted in human patients to evaluate the 
efficacy of i.t. adenosine on alleviating pain, and none have specifically looked at the effect of 
adenosine on treating signs and symptoms associated with painful diabetic neuropathy [195]. 
Belfrage et al. evaluated the efficacy of i.t. adenosine and found that spontaneous and evoked 
pain were reduced in a small cohort of patients, with transient low back pain the only reported 
side effect [87]. As a follow up, Eisenach et al. evaluated the efficacy of i.t. vs. i.v. delivery of 
adenosine and found that i.v. administration of adenosine effectively reduced the area of 
allodynia and evoked pain in the area of allodynia [88]. A clinical trial evaluating the efficacy of 
a novel A2AR agonist for the treatment of diabetic neuropathic pain was well tolerated by 
showed no significant improvement in pain symptoms [173]. The work presented here shows 
that activation of A1R is effective in treating pain-like symptoms associated with diabetic 
neuropathy, and warrants inclusion of patients with painful diabetic neuropathy in clinical trials 
evaluating the efficacy of adenosine as a treatment modality for neuropathic pain.  
Decreased cAMP production and increased Akt activation contribute to the antinociceptive 
effects of A1R activation following central delivery of A1R agonists 
All adenosine receptors are GPCRs and activation causes dissociation of the associated 
heterotrimeric G-protein, which further subdivides into an α-subunit and a βγ-subunit. Each of 
these subunits can then independently activate many different downstream signaling cascades, 
resulting in major amplification of cellular signals. Classically, A1R activation is linked to 
inhibition of andenylyl cyclase through activation of Gαi, leading to decreased production of 
cAMP levels [138]. Interestingly, following i.t. delivery of Ado + ITU, cAMP levels in the 
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spinal cord were significantly decreased compared to baseline levels, and had still not recovered 
at 5 hours following treatment. This correlates with the observed behavioral outcomes in which 
diabetic mice that received i.t. Ado + ITU displayed mechanical withdrawal thresholds that were 
significantly elevated over diabetic vehicle treated mice, and that were not significantly different 
from nondiabetic mice, an effect that last over 5 hours. Several substrates and genes are 
regulated downstream of cAMP, and future studies should investigate the contribution (or 
inhibition) of these to A1R-mediated antinociception in the context of painful diabetic 
neuropathy. 
High levels of A1R protein are seen in adipose tissue, and activation of the receptor 
reduces the breakdown of triglycerides into free fatty acids (FFAs), an act that is mediated 
through inhibition of cAMP production and therefore PKA activation, which in turn inhibits the 
actions of hormone-sensitive lipase and adipose triglyceride lipase [196, 197]. Type 2 diabetes is 
largely associated with peripheral insulin resistance and obesity [2-5, 28], and individuals with 
diabetes are more likely to have dyslipidemia than the general population [198]. Dyslipidemia is 
defined as increased levels of plasma triglycerides, low levels of circulating HDL, and increased 
levels of LDL, and is associated with the development of cardiovascular disease [199]. Recently, 
Guilford et al. has shown that diabetic mice fed a high-fat diet results in dyslipidemia and 
phenotypic switching from an insensate neuropathy to a painful neuropathy, suggesting that 
circulating levels of  FFAs may influence the development of diabetic neuropathy [200]. 
Combining this observation with the work presented in this document, it would be interesting to 
explore the effect of adenosine and A1R activation in a high-fat model of type 2 diabetes, and to 
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determine if activation of A1R could also reverse signs of mechanical allodynia in this model of 
painful diabetic neuropathy.  
Currently, a majority of the literature reports activation of Akt as an intracellular 
mediator of nociceptive neurotransmission. However, we show that Akt is robustly activated 
following i.t. administration of both Ado + ITU and CPA that correlates with improved 
mechanical withdrawal thresholds in diabetic mice, and this activation is elevated in diabetic 
mice compared to nondiabetic mice. This suggests a role of Akt activation in mitigating pain 
transmission, rather than propagating pain transmission. The A1R can exist as part of a receptor 
complex, and has been shown form heteromultimers with µ- and δ-opioid receptors [52, 177, 
201]. Activation of Akt is seen in the periphery following administration of µ-opioid agonists, 
resulting in inhibition of inflammatory hyperalgesia [164, 165]. Clearly, further understanding of 
the role of Akt signaling in mediating the antinociceptive outcomes observed following central 
activation of A1R is needed.  
Calcium channel expression and signaling is dysregulated in painful diabetic neuropathy  
 Calcium channel signaling is involved in many physiological processes, and is intimately 
involved in neuronal function, including modulation of neuronal excitability and 
neurotransmitter release [150, 202]. Furthermore, calcium channel dysregulation is strongly 
associated with neuronal disease, particularly in the case of diabetic neuropathy [150]. Kostyuk 
et al. report increased [Ca2+]i in neurons from diabetic mice and rats, suggesting that diabetes has 
a general effect on the ability of neurons to regulate intracellular calcium stores in the setting of 
diabetes. At 8 weeks post STZ-induction of diabetes, we showed increased calcium flux through 
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neurons following stimulation with the TRPV1 agonist, capsaicin, supporting the notion that 
diabetes affects calcium signaling in neurons from diabetic animals.  
It should be noted that this analysis included all cells that responded to capsaicin, not just 
small-diameter neurons, although this subset of neurons is primarily the subset that expresses 
TRPV1. Initial experiments attempted to label IB4+ neurons, however, the presence of the 
antibody interfered with calcium signaling and data acquisition; these experiments were not 
included in data analysis. Back-labeling of neurons with DiI would allow identification of 
neurons that project to the hind paws of diabetic mice, thus allowing evaluation of calcium flux 
through this specific population. However, this presents its own unique set of challenges in the 
face of diabetic neuropathy given the neurodegenerative nature of diabetic neuropathy and the 
‘dying-back’ phenomenon. Nonetheless, it would allow for determination of changes in calcium 
signaling in surviving neurons from diabetic mice. Additionally, these experiments were 
performed at a terminal time point, at which time diabetic mice displayed significant allodynia. 
Determination of changes in calcium signaling at earlier time points would shed light on the time 
course of diabetes-induced changes in calcium homeostasis. The use of specific agonists and 
antagonists would add further insight into the role of specific calcium channels and receptor-
specific modulation of calcium signaling. 
 Activation of A1R is known to inhibit P-, Q- and N-type calcium channels [81]. 
Dysregulation of N-type (Cav2.2) channels has been reported in diabetic rats, and this 
dysregulation was associated with impaired G-protein modulation of calcium channel signaling 
[167]. Here, were show that diabetes affects generation of adenosine (through inhibition of 
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ectonucleotidase-mediated hydrolysis of AMP), which in turn results in decreased activation of 
A1R, leading to decreased G-protein modulation of calcium channels and dyregulation of 
calcium homeostasis. Indeed, we show that incubation of primary DRG cultures with adenosine 
returns the increased calcium flux in neurons from diabetic mice to control levels, supporting the 
notion that calcium channels are regulated by G-proteins, specifically the βγ-subunit [203]. 
Repeating these experiments with the A1R specific agonist, CPA, would further support the 
claim that decreased A1R activation, as a result of decreased adenosine production, leads to 
altered calcium homeostasis subsequent to decreased G-protein inhibition of calcium channel 
signaling. Additionally, use of βγ-subunit specific inhibitors would add tremendous support to 
this theory. 
Finally, several studies report upregulation of the α2δ-subunit of calcium channels 
following nerve injury [151, 169, 170, 204]. Interestingly, this is the molecular target for 
gabapentin and pregabalin [205]. We evaluated protein levels of the α2-subunit (the α2-subunit 
and the δ-subunit dissociate under reducing conditions used for Western blot analysis) and did 
not see any significant changes in diabetic mice. However, these studies were conducted at a 
terminal time point so it is possible that temporal regulation affects the window of detection for 
upreglation of the α2δ-subunit of calcium channels.  
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Peripheral delivery of specific A1R agonist reveals a novel mechanism for the treatment of 
painful diabetic neuropathy 
 First-line treatment options for neuropathic pain, as recommended by the Neuropathic 
Pain Special Interest Group of the IASP, include tricyclic antidepressants, serotonin-
norepinephrine reuptake inhibitors, calcium channel modulators (ex: gabapentin and pregabalin) 
and topical lidocaine [33]. Current treatment options for painful diabetic neuropathy include the 
use of all of these agents, with gabapentin, pregabalin and duloxetine topping the list as the most 
effective agents [117]. However, the efficacy of these medications varies between individuals, 
and many carry significant risk of systemic adverse effects [17, 34, 206]. Ulugol et al. report that 
the anti-allodynic effect of amitriptyline in diabetic rats involves adenosinergic signaling [207], 
providing some of the only evidence to date that adenosine is effective at alleviating mechanical 
allodynia associated with diabetic neuropathy.  
 Data presented in this dissertation support the theory that peripheral administration of 
adenosine is pro-nociceptive. Diabetic mice that received i.pl. Ado + ITU remained allodynic 
throughout the duration of the experiment, and nondiabetic mice treated with i.pl. Ado + ITU 
hewed a decreased in withdrawal thresholds that was not significantly different from diabetic 
Ado + ITU treated mice. Surprisingly, we found that peripheral activation of A1R with the 
specific A1R agonist, CPA, effectively alleviated mechanical allodynia in diabetic mice. This 
experiment should be repeated to increase the number of mice included in this study, as the 
current study was the last behavioral experiment conducted and fewer than anticipated mice 
survived to the time point at which the pharmacological interventions were performed.  
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The results of this study are extremely encouraging when considering translation of this 
body of work into potential treatment options for the management of painful diabetic neuropathy. 
The behavioral outcomes seen following i.pl. administration of CPA warrant further 
investigation into peripheral activation of A1R-mediated antinociceptive pathways for the 
treatment of painful diabetic neuropathy. Topical creams, such as capsaicin and lidocaine, have 
shown success for the treatment of other neuropathic pain syndromes, including painful diabetic 
neuropathy, PHN, and HIV-induced neuropathy [33, 45]. The data presented here are currently 
one of the only in vivo studies to show that A1R activation in the periphery is an effective target 
for the treatment of painful diabetic neuropathy. When translating this body of work to humans, 
knowing that this antinociceptive pathway is accessible from periphery allows future 
development of treatment regimens which take advantage of a peripheral route of delivery rather 
than a systemic route (oral or i.v.), thus minimizing the potential for the development of systemic 
adverse effects. To avoid injection-induced tissue injury and inflammation, development of 
topical creams that allow for diffusion of CPA or other A1R-specific agonists into the skin would 
have major therapeutic treatment potential not only for painful diabetic neuropathy, but 
presumably many types of peripheral pain syndromes. 
Overall Conclusions 
The work presented in this dissertation contributes significant understanding into the role 
of adenosinergic signaling in the context of painful diabetic neuropathy. Adenosine is an 
important neuromodulator involved in many processes related to nervous system health and 
disease. Adenosine receptors are ubiquitously expressed throughout the body, with certain 
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receptors more prominent in specific tissues. Specifically, A1R is highly concentrated in the 
DRG and spinal cord, and activation of this receptor is involved in counteracting pro-nociceptive 
puringergic signaling. The work present herein shows that diabetes significantly affects 
endogenous adenosine production, thus releasing nociceptive neurons from tonic inhibitory 
regulation, in addition to altered expression of A1R in the central nervous system of diabetic 
mice. Pathway function is conserved, however, because central and peripheral activation of A1R 
results in significant improvement of mechanical withdrawal thresholds in diabetic mice. 
Furthermore inhibition of cAMP production and activation of Akt were identified as potential 
downstream messengers involved in mediating these antinociceptive outcomes. Finally, 
improved mechanical withdrawal thresholds following peripheral delivery of an A1R-specific 
agonist shows that activation of this pathway has practical applications for translation of this 
work into a therapy for individuals suffering from painful diabetic neuropathy.  
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